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A B S T R A C T
Background
Postoperative vitreous cavity haemorrhage (POVCH) is a significant complication following vitrectomy for proliferative diabetic
retinopathy (PDR). It delays visual recovery and can make further treatment difficult if the view of the fundus is significantly obscured.
A number of interventions to reduce the incidence of POVCH have been proposed, including the perioperative use of anti-vascular
endothelial growth factor (anti-VEGF). Anti-VEGFs reduce vascular proliferation and the vascularity of neovascular tissue, which is
often the source of bleeding following vitrectomy.
Objectives
This updated review aimed to summarise the effects of anti-VEGF use to reduce the occurrence of POVCH after vitrectomy surgery
for PDR.
Search methods
We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2015, Issue 4), Ovid MEDLINE,
Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to
May 2015), PubMed (January 1966 to May 2015), EMBASE (January 1980 to May 2015), Latin American and Caribbean Health
Sciences (LILACS) (January 1982 to May 2015), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (
www.clinicaltrials.gov), and the the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (
www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched
the electronic databases on 26 May 2015.
Selection criteria
We included all randomised controlled trials (RCTs) and quasi-RCTs that looked at the use of anti-VEGFs and the incidence of
POVCH in people undergoing vitrectomy for PDR.
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Data collection and analysis
Both review authors independently assessed and extracted the data.We used standard methodological procedures expected by Cochrane.
The primary outcomes of the review were the incidence of early and late POVCH following perioperative anti-VEGF administration.
Secondary outcomes included best-corrected visual acuity at six months following surgery, the incidence of vitreous cavity washout or
revision vitrectomy at six months, adverse effects of intervention (cataract, iris rubeosis and rubeotic glaucoma, retinal detachment,
increased inflammation and systemic side effects), quality of life measures performed at least six months following vitrectomy, and
density of POVCH.
Main results
The current review included 12 RCTs that looked at the pre- or intraoperative use of intravitreal bevacizumab to prevent postoperative
vitreous haemorrhage during pars plana vitrectomy for complications of PDR.The studies were conducted in a variety of countries (three
from Iran, two from Italy, two from Egypt, and the remaining from South Korea, USA, Mexico, Pakistan, and Japan). The inclusion
criteria for entry into the studies were standard complications of proliferative retinopathy: non-clearing vitreous haemorrhage, tractional
retinal detachment involving the macula, or combined tractional rhegmatogenous detachment. The included studies randomised a
total of 654 eyes. The average age of the participants was 54 years.
We identified methodological issues in all included studies. Risk of bias was highest for masking of participants and investigators (four
studies were an ’open label’ design), and a number of studies were unclear when describing randomisation methods and sequence
allocation.
Participants receiving intravitreal bevacizumab in addition to pars plana vitrectomy were less likely to experience early POVCH (grade
2) compared to people undergoing pars plana vitrectomy alone (risk ratio (RR) 0.28, 95% confidence interval (CI) 0.08 to 0.96, 2
studies, 144 eyes, high-quality evidence). This corresponds to an absolute effect of 130 fewer people (95% CI 167 fewer to 7 fewer)
with early POVCH per 1000 people when treated with intravitreal bevacizumab. We saw similar results for all grades of POVCH (RR
0.35, 95% CI 0.23 to 0.53, 9 studies, 512 eyes) and when excluding cases where assessment of outcome was impossible due to presence
of silicone oil (RR 0.34, 95% CI 0.19 to 0.60, 6 studies, 302 eyes).
The effect of pre- or intraoperative intravitreal bevacizumab on the incidence of late postoperative haemorrhage was uncertain (RR
0.72, 95% CI 0.30 to 1.72, 3 studies, 196 eyes, low-quality evidence). The absolute effect was 55 fewer people (95% CI 138 fewer
to 143 more) with late POVCH per 1000 people when treated with intravitreal bevacizumab. This outcome was rarer and was only
reported in a few studies. We are currently unable to provide an estimate of the effect of intravitreal bevacizumab on postoperative
visual acuity due to significant study heterogeneity.
No local or systemic complications of intravitreal bevacizumab were reported by the RCTs. The risk of postoperative retinal detachment
was lower in the participants treated with pre- or intraoperative bevacizumab (RR 0.46, 95%CI 0.19 to 1.08, 7 studies, 372 participants,
low-quality evidence); the absolute effect was 49 fewer people (95% CI:73 fewer to 8 more) with postoperative retinal detachment per
1000 people when treated with intravitreal bevacizumab.
Authors’ conclusions
The use of pre- or intraoperative bevacizumab lowers the incidence of early POVCH. The reported complications from its use appear
to be low. Futher randomised studies that look at other anti-VEGF medications are ongoing and will strengthen the current review
findings, giving both surgeons and patients evidence to guide treatment choices in the management of proliferative retinopathy.
P L A I N L A N G U A G E S U M M A R Y
Anti-VEGF for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy
Review question
Does anti-vascular endothelial growth factor (anti-VEGF) reduce the occurrence of posterior vitreous cavity haemorrhage (POVCH)
after vitrectomy surgery for proliferative diabetic retinopathy?
Background
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POVCH is a significant complication following vitrectomy (removal of the vitreous gel from the posterior chamber of the eye) for the
treatment of proliferative retinopathy (the growth of abnormal blood vessels from the retina, a layer of tissue at the back of the eye),
occurring in approximately 30% of cases. POVCH has two main forms: early, when haemorrhage (bleeding) is present in the first
few postoperative days, and late, when haemorrhage occurs a number of months after surgery. The presence of POVCH delays visual
recovery, can lead to elevated pressure within the eye, and can make further treatment for diabetic retinopathy difficult. Ten per cent of
patients require revision surgery, which has significant implications for resources, time, and cost. The use of anti-VEGF before surgery
(preoperatively) has been proposed as an intervention to reduce the incidence of POVCH.
Search date
The evidence is up to date to May 2015.
Key results
The electronic database searches identified 12 randomised controlled trials that met the inclusion criteria. We performed a number of
analyses that suggest that pre- or intraoperative anti-VEGF may reduce the incidence of early POVCH. The effect on late POVCHwas
unclear. We are currently unable to comment on the effect of anti-VEGF treatment on postoperative visual acuity due to significant
differences in the studies’ design and outcomes.
The risk of adverse events when using preoperative anti-VEGF appears small.
Quality of evidence
We are reasonably certain that anti-VEGF reduces the incidence of early POVCH (high-quality evidence) but less certain about its
effects on late POVCH and risk of adverse effects.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Anti-VEGF compared with control for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy
Patient or population: People with proliferative diabetic retinopathy undergoing vitrectomy
Settings: Hospital
Intervention: Anti-VEGF
Comparison: No anti-VEGF
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Anti-VEGF
Early POVCH
4 weeks
182 per 1000 52 per 1000
(15 to 175)
RR 0.28 (0.08 to 0.96) 144
(2)
⊕⊕⊕⊕
high
POVCH grade 2 or worse
Early POVCH
4 weeks
310 per 1000 109 per 1000
(71 to 164)
RR 0.35 (0.23 to 0.53) 512
(9)
⊕⊕⊕⊕
high
POVCH all grades
Late POVCH
6 months
198 per 1000 143 per 1000
(60 to 341)
RR 0.72 (0.30 to 1.72) 196
(3)
⊕⊕©©
low1
POVCH all grades
Visual acuity logMAR
acuity
6 months
The mean visual acu-
ity ranged across control
groups from 0.51 to 2.07
logMAR
Due to substantial hetero-
geneity between studies
(I2 = 88%), we could not
estimate a treatment ef-
fect and hence a corre-
sponding risk
Mean differences ranged
from 1.31 logMAR in
favour of anti-VEGF to 0.
14 logMAR in favour of
control
289
(5)
We did not GRADE this as
we do not have an esti-
mate of effect
Vitreous cavity washout
6 months
70 per 1000 15 per 1000
(3 to 74)
RR 0.19 (0.06 to 0.67) 291
(5)
⊕⊕©©
low2
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Adverse effects: retinal
detachment
at any time
91 per 1000 42 per 1000
(18 to 99)
RR 0.46 (0.19 to 1.08) 372
(7)
⊕⊕©©
low3
Other ad-
verse events considered
included: raised intraoc-
ular pressure, rubeo-
sis, neovascular glau-
coma, cataract progres-
sion, systemic adverse
events. Not much data
available/reported
Quality of life
6 months
Not reported
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; MD: Mean difference; RR: Risk ratio; POVCH: Postoperative vitreous cavity haemorrhage; VEGF: Vascular endothelial growth factor.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgraded for imprecision (confidence intervals include 1 (no effect)) and indirectness (the analysis includes all grades of POVCH,
but we planned to consider only grade 2 or worse).
2Downgraded for risk of bias (none of the trials contributing to this analysis reported methods of sequence generation and allocation
concealment in enough detail to judge risk of bias) and imprecision (confidence intervals include 1 (no effect)).
3Downgraded for risk of bias (all except one of the trials contributing to this analysis reported methods of sequence generation and
allocation concealment in enough detail to judge risk of bias) and imprecision (confidence intervals include 1 (no effect)).
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B A C K G R O U N D
Description of the condition
Pars plana vitrectomy is an established and successful treatment for
the complications of proliferative diabetic retinopathy (PDR) (Ho
1992; McLeod 1991). Up to 10% of people presenting with PDR
require the treatment within one year (Kaiser 2000). The most
common indication for surgery is non-clearing vitreous haem-
orrhage (Ho 1992; McLeod 1991). Unfortunately, postoperative
vitreous cavity haemorrhage (POVCH) is a significant complica-
tion occurring in approximately 20% to 30% of cases, although
the reported range is large: 5% to 80% of cases (Benson 1988;
Blankenship 1986; Liggett 1987; Novak 1984; Tolentino 1989;
Virata 2001; Yorston 2008).
Although there can be overlap, POVCHoccurs in twomain forms.
1. Early POVCH, being present from the first few
postoperative days and delaying visual recovery by non-clearance.
2. Late POVCH, occurring later during follow-up, commonly
at two to six months postoperatively, after a postoperative period
during which the vitreous cavity was clear.
Aetiology of POVCH
Persistent haemorrhage can result from operative and postopera-
tive oozing of the remnants of new vessels or dissected tissue, or
directly from the sclerostomies used to perform surgery. It can also
occur from clot lysis in the first few postoperative days. Leach-
ing of red blood cells can occur from retained old haemorrhages
in residual anterior vitreous, causing apparent POVCH (McLeod
1991; Novak 1984; Tolentino 1989).
Recurrent haemorrhage can result from late haemorrhage from
dissected tissue, recurrent traction on residual new vessels, or in-
deed postoperative new vessel growth in the posterior retina. Re-
cent studies have shown that a common cause of recurrent haem-
orrhage is new anterior vessel growth at the inner sclerostomy sites
associated with fibrous traction (Bhende 2000;Hershberger 2004;
Hotta 2000; Kreiger 1993; Sawa 2000; Steel 2008; West 2000).
Termed ‘entry site neovascularisation’ (ESNV) (McLeod 2000),
this is thought to be an aberrant wound-healing response related
to the presence of retinal and pars plana ischaemia (Kreiger 1993;
Yeh 2005). The presence of ESNV is difficult to observe clinically
because of the extreme anterior location, but can be confirmed at
the time of revision surgery with deep scleral indentation or endo-
scopic techniques (West 2000). It can also be localised, with ante-
rior segment high-resolution ultrasonography of the inner scleros-
tomy sites (Bhende 2000; Hershberger 2004; Hotta 2000; Steel
2008).
Consequences and management of POVCH after
occurrence
People with POVCH suffer a delay in their visual recovery which,
in some cases, results in a worse level of visual acuity than preop-
eratively. Intraocular pressure can become raised from trabecular
meshwork obstruction. If maculopathy is present, then additional
laser treatment cannot be applied, with the risk of worsening foveal
function in the long term.
The initial treatment for POVCHis observation (Tolentino 1989).
Spontaneous clearance occurs in many cases. Because they are
no longer trapped in the gel structure of the vitreous, red blood
cells can circulate and clear more freely from the vitreous cavity.
Clearance is related to the amount of haemorrhage, its frequency,
and the degree of communication between anterior and posterior
segments, allowing red blood cells to enter the anterior chamber
and be cleared via the trabecular meshwork (McLeod 2000).
Non-clearing POVCH necessitates revision surgery in approxi-
mately one-third to one-half of those who experience POVCH
and approximately 10% of all patients undergoing surgery (
Blankenship 1986; Blumenkranz 1986; Brown 1992; Han 1991;
Martin 1992;Novak 1984; Schachat 1983;Tolentino 1989).Non-
clearing POVCH is treated with surgery to remove haemorrhage
and to treat any underlying cause that may have been identified.
The timing of the surgery will depend on a variety of factors, in-
cluding social situation, fellow-eye status, maculopathy needing
treatment, intraocular pressure, etc.
In some patients, spontaneous clearing or revision surgery is fol-
lowed by further haemorrhage, frustrating visual rehabilitation
further, especially if this occurs in the better eye.
Description of interventions to reduce the
incidence of POVCH and how the interventions
may work
At the time of the initial vitrectomy surgery, several strategies may
have been used to prevent POVCH and avoid the need for repeat
surgery. We can divide these into two main groups.
1. Established surgical interventions that are generally
regarded as standard clinical practice.
i) Ensuring adequate haemostasis at the time of
vitrectomy with laser or intraocular bipolar coagulation to reduce
postoperative oozing of dissected blood vessels.
ii) Removal of peripheral haemorrhagic vitreous to
reduce leaching of sequestered red blood cells postoperatively
into the vitreous cavity.
iii) Identification and removal of all posterior vitreoretinal
traction. Vitreoschisis is also known to occur in people with
PDR, and identification of this and dissection in the true
vitreoretinal plane are important in order to avoid recurrent
traction and postoperative bleeding from neovascular tissue
(Schwatz 1996).
iv) Applying supplementary posterior panretinal
photocoagulation if required.
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2. Other strategies to prevent POVCH that have been
reported but not routinely adopted.
Surgical
• Applying additional anterior retinal photocoagulation up to
the ora serrata to ablate retro-oral ischaemic retina and reduce
the production of postoperative neovascular growth factors
(Liggett 1987; Mason 1978; Yeh 2005).
• Direct treatment to the sclerostomy sites themselves with
either cryotherapy or laser (Yeh 2005). This is thought to reduce
the occurrence of entry site neovascularisation by inhibiting
cellular migration through the sclerostomy wounds and causing
focal atrophy of the ciliary epithelia.
• Removal of Wieger’s ligament and thorough anterior
vitrectomy, especially around the inner sclerostomy wounds
(McLeod 2000; McLeod 2003). This may be effective by:
◦ increasing the egress of red blood cells and growth
factors from the posterior segment to the anterior segment for
rapid clearance of any POVCH;
◦ reducing any putative concentration of growth factors
around the sclerostomy sites themselves;
◦ removing the vitreous scaffold along which anterior
new vessels could grow.
Some clinicians advocate simultaneous or even pre-emptive
cataract surgery to achieve these aims and reduce the risk of
POVCH (Schiff 2007).
• Agents with physical actions thought to possibly reduce the
rate of POVCH inserted into the eye during surgery, such as air
(Joondeph 1989), gas (Koutsandrea 2001; Yang 2007), or
viscoelastic substances (Packer 1989).
Pharmacologic
Preoperative
• The vascular endothelial growth factor (VEGF) inhibitor
bevacizumab has been used preoperatively to reduce vascular
proliferation and reduce the vascularity of neovascular tissue
(Romano 2009a; Yang 2008).
Intraoperative
• Triamcinolone has been used intraoperatively by intraocular
injection to reduce inflammation and vascular proliferation
(Faghihi 2008).
• Bevacizumab has been used intraoperatively to reduce
vascular proliferation following surgery (Romano 2009b).
Postoperative
• Oral tranexamic acid, which inhibits fibrinolysis and hence
clot dissolution, administered to the patient postoperatively
(Laatikainen 1987; Ramezani 2005).
Why it is important to do this review
Diabetes mellitus is an increasing health problem. It is estimated
that 6% (3.2 million) of the UK population are currently diabetic
and that this will increase to 5 million by 2025. Ten per cent (10
billion UK pounds) of the total NHS budget is spent treating the
acute costs of diabetes and its complications and this is predicted
to increase to 17 billion by 2035 (Diabetes UK 2014). Diabetic
retinopathy is one of the leading cause of blindness in the working
age group in the UK accounting for 14.4% of blind and partially
sighted registrations (Liew 2014).
Within 20 years of diagnosis nearly all people with Type 1 and
almost two thirds of people with Type 2 diabetes have some degree
of retinopathy (Scanlon 2008) and after 15 years, 30% and 10%
of type 1 and type 2 diabetics respectively develop PDR (Klein
1984a; Klein 1984b). These patients are at risk of severe visual loss
resulting from the complications of PDR. A study of patients at
a large eye unit in the USA suggested that approximately 10% of
patients presenting with PDR require vitrectomy surgery within
one year (Kaiser 2000). Estimates based upon data fromour region
(Vaideanu 2014) suggest that approximately 4000 vitrectomies for
the complications of PDR are currently performed annually in the
UK. If 10% require revision surgery, this equates to 400 patients
per annum in the UK. POVCH after vitrectomy surgery is cer-
tainly a significant problem and its occurrence is distressing for
patients as well as delaying visual recovery. Repeat interventions
expose the patient to further operative risk and anxiety and add to
the overall cost of care. The use of anti-VEGF treatment is becom-
ing increasingly common formany ophthalmic conditions and has
significant revenue consequences. The result of anti-VEGF use,
both preoperatively and intraoperatively, to reduce the occurrence
of POVCH is uncertain, and a review of the literature will aid in
optimum patient management and design of future studies.
The use of anti-VEGF treatment is becoming increasingly com-
mon for many ophthalmic conditions and has significant revenue
consequences. However, the effectiveness of anti-VEGF use, both
preoperatively and intraoperatively, in reducing the occurrence of
POVCH is uncertain. A review of the literature will aid in opti-
mum patient management and in the design of future studies.
O B J E C T I V E S
This review aimed to summarise the effects of anti-VEGF use to
reduce the occurrence of POVCH after vitrectomy surgery for
PDR.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
This review aimed to include all randomised controlled trials
(RCTs) and quasi-RCTs. If we had not found any RCTs that met
our inclusion criteria, we would have provided a description of the
evidence for current practice from non-randomised comparative
trials along with the nature of evidence on which the review was
based. We imposed no language or date restrictions.
Types of participants
Participants in the trials had to be people with PDR undergoing
vitrectomy for the complications of diabetic retinopathy for the
first time.
Types of interventions
Intervention: any use of anti-VEGF designed to reduce POVCH.
We considered the following anti-VEGF treatments when given
pre- or intraoperatively.
• Bevacizumab 1.25 mg/0.05 ml
• Ranibizumab 0.5 mg/0.05 ml
• Pegaptanib 0.3 mg/0.05 ml
• Aflibercept 2.0 mg/0.05 ml
Comparator: no treatment, sham treatment, or any other anti-
VEGF.
Types of outcome measures
As the aim of this review was to look at the prevention of POVCH,
we excluded studies that did not report POVCH.
Primary outcomes
1. The incidence of early POVCH after surgery. We defined
early POVCH as haemorrhage present from the first
postoperative day or recurrent within four weeks postoperatively,
either being at least grade 2 in severity as measured by the
Diabetic Retinopathy Vitrectomy Study criteria (Anonymous
1985).
2. The incidence of late POVCH after surgery. We defined
late POVCH as haemorrhage occurring more than four weeks
postoperatively after a period during which the vitreous cavity
was clear. The minimum length of follow-up for this outcome
was six months.
Secondary outcomes
1. Visual acuity at six months following the primary
vitrectomy.
2. The incidence of vitreous cavity washout or revision
vitrectomy at six months.
3. Adverse effects of intervention including cataract, iris
rubeosis and rubeotic glaucoma, retinal detachment, increased
inflammation and systemic side effects.
4. Quality of life measures performed at least six months
following vitrectomy.
5. Density of POVCH, as measured by the Diabetic
Vitrectomy Study criteria (Anonymous 1985).
Follow-up
Follow-up for the reviewed studies’ outcome measures varied from
1 month to 12 months postvitrectomy. We looked at studies with
any follow-up period, using six-month follow-up data as a min-
imum for late POVCH and visual acuity. Follow-up periods for
the remaining secondary outcomes varied and are described in the
Characteristics of included studies section.
Search methods for identification of studies
Electronic searches
We searched CENTRAL (which contains the Cochrane Eyes and
Vision Group Trials Register) (2015, Issue 4), Ovid MEDLINE,
Ovid MEDLINE In-Process and Other Non-Indexed Citations,
Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946
to May 2015), PubMed (January 1966 to May 2015), EMBASE
(January 1980 to May 2015), Latin American and Caribbean
Health Sciences (LILACS) (January 1982 to May 2015), the IS-
RCTN registry (www.isrctn.com/editAdvancedSearch), Clinical-
Trials.gov (www.clinicaltrials.gov), and the the World Health Or-
ganization (WHO) International Clinical Trials Registry Platform
(ICTRP) (www.who.int/ictrp/search/en).We did not use any date
or language restrictions in the electronic searches for trials. We last
searched the electronic databases on 26 May 2015.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1), MEDLINE (Appendix 2), PubMed (Appendix
3), EMBASE (Appendix 4), LILACS (Appendix 5), ISRCTN (
Appendix 6), ClinicalTrials.gov (Appendix 7), and the ICTRP
(Appendix 8).
We ran the initial searches both with and without RCT search
filters, as we wished to identify as much literature as possible
on POVCH. For subsequent updates, however, we will only run
searches with RCT filters, as the review is focusing on evidence
from RCTs only.
After editorial input, we decided to revise and broaden the search
strategies for the review. The searches were constructed of terms
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for the following four components: diabetic retinopathy, vitrec-
tomy, haemorrhage, anti-VEGF drugs. The searches have now
been amended whereby the terms for vitrectomy and for haemor-
rhage have been combined into one search set of terms. This has
made the search broader and will help us to identify additional
relevant studies.
Searching other resources
We manually searched the reference lists of the trials included in
the review for additional trials. We did not specifically handsearch
journals or conference proceedings for this review.
Data collection and analysis
Selection of studies
Both review authors independently assessed abstracts to ascertain
which studies met the inclusion criteria for the review. We labelled
the abstracts as included, unclear, or excluded. We obtained full-
text copies of all included and unclear studies, and we indepen-
dently determined which studies met the inclusion criteria. We
again labelled each study as included, unclear, or excluded. We
discussed any unclear articles and contacted the authors of the
relevant article for further details when necessary.
Data extraction and management
Both review authors independently extracted data using stan-
dard methodological procedures expected by Cochrane. We com-
pared each data set and resolved any discrepancies by discussion.
We independently entered data into Review Manager and then
rechecked the data (RevMan 2014).
Assessment of risk of bias in included studies
We structured the criteria for assessment of risk of bias per Chapter
8 of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).We assessed each domain area, giving a judgement
of ’low’ risk of bias, ’high’ risk of bias, or ’unclear’ risk of bias. A
judgement of ’unclear’ indicated we were uncertain of the risk of
bias. We looked specifically at the following domain areas:
• Methods used to generate the study groups.
• Methods used to conceal the allocation of the study groups.
• Methods used to mask (blind) study participants and
personnel.
• Review of the study outcome data, looking specifically at
the completeness of each study group outcome and selective
outcome reporting.
Measures of treatment effect
Wepresented dichotomous outcomes as risk ratios and continuous
outcomes as mean difference.
The review’s primary outcomes included dichotomous data on the
incidence of persistent or early POVCH and the incidence of late
POVCH following the primary surgery. The secondary outcome
data contained dichotomous data on the incidence of vitreous
cavitywashout or revision vitrectomy at sixmonths and the adverse
effects of the intervention. We intended to analyse visual acuity at
six months following the primary vitrectomy as continuous data.
POVCH density is graded into four categories: grades 0 to 3.
Rather than analysing the data as ordinal outcomes, we proposed
to group together grade 0 with grade 1 POVCH and grade 2 with
grade 3 POVCH in order to generate two larger groups, which we
planned to analyse as dichotomous data in a meta-analysis.
Unit of analysis issues
Ahn 2011 and Manabe 2015 included a small number of partic-
ipants who had both eyes randomised. We included these partic-
ipants in the analysis. Due to the number being small, we con-
sidered that the effect of interpersonal variance on any outcome
would be negligible.
Dealing with missing data
Where data were missing in the included studies, we contacted
the authors of the trials to request the missing data. In studies for
which the trial authors could not provide missing data, we assessed
whether the missing data were of ’low’ or ’high’ risk of bias, as
per Chapter 8 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011).
We intended to include studies missing data considered to be of
’low’ risk of bias in a meta-analysis. We would also have included
studies thought to be at ’high’ risk of bias in the meta-analysis, but
we would have performed a sensitivity analysis in order to assess
their impact on the outcome of the meta-analysis.
Assessment of heterogeneity
We assessed clinical heterogeneity by careful review of the study
papers and presented a descriptive summary of results.We assessed
heterogeneity between studies included in the meta-analysis using
the I2 statistic. We took an I2 result of more than 50% as an
indication of high study heterogeneity.
Assessment of reporting biases
To avoid the presence of reporting biases within the review, we
searched trial registry databases, which allowed us to identify all
registered trials, published and unpublished. We contacted inves-
tigators of registered trials that were listed as having completed
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participant recruitment to ask for any unpublished data that may
be relevant to the review outcomes.
Data synthesis
We performed analysis of data from the included RCTs for the
two primary outcomes, secondary outcomes 1 and 2, and also
for rate of postoperative retinal detachment. We used a random-
effects model for any analysis containing three or more RCTs.
Sensitivity analysis
We excluded trials that included participants with silicone oil tam-
ponade because we felt that the tamponade could affect the assess-
ment of the outcomes.
Summary of findings table
We prepared a ’Summary of findings’ table presenting relative
and absolute risks. We graded the overall quality (certainty) of
the evidence for each outcome using the GRADE classification
(GRADEpro 2014). We included the following outcomes in the
’Summary of findings’ table.
1. Early POVCH (four weeks)
2. Late POVCH (six months)
3. Visual acuity, logMAR (six months)
4. Vitreous cavity washout (six months)
5. Adverse events: retinal detachment (at any time)
6. Quality of life
These outcomes were not defined a priori because the original
protocol and first edition of this review were published before the
summary of findings methodology was adopted by the Cochrane
Eyes and Vision Group.
R E S U L T S
Description of studies
Results of the search
The electronic searches yielded a total of 472 titles and abstracts
and 9 reports of ongoing studies. After deduplication, the Tri-
als Search Co-ordinator scanned 397 records and discarded 311
records that were not relevant to the scope of the review. We
screened the titles and abstracts of the remaining 86 references.We
rejected 70 abstracts as not eligible for inclusion in the review. We
obtained and screened full-text copies of 16 references, of which
we included 4 studies and excluded 12 studies from the review.
The amended searches run in May 2015 retrieved a total of 1414
records (Figure 1). After removing duplicate records, we screened
1138 references and excluded 1110 records that were not relevant
to the scope of the review. We assessed 28 full-text reports of
studies for potential inclusion in the review. In addition to the
four previously included studies (Ahmadieh 2009; di Lauro 2009;
Modarres 2009; Rizzo 2008), we have now included eight new
studies (Ahn 2011; El Batarny 2008; Elwan 2013; Farahvash 2011;
Hernández-Da Mota 2010; Manabe 2015; Sohn 2012; Zaman
2013). We excluded 12 studies (Berk Ergun 2014; Bhavsar 2014;
Demir 2013; Goncu 2014; Gupta 2008; Gupta 2012a; Gupta
2012b; Jirawison 2012; Li 2010; Pakzad-Vaezi 2014; Pokroy 2011;
Sato 2013). We previously excluded da R Lucena 2009 and Yeh
2009 at the initial stage of screening abstracts. However, these two
studies have been included in a meta-analysis by Zhao 2011, so in
the interests of transparency we have now added these studies to
our list of excluded trials with reasons for exclusion.
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Figure 1. Results from searching for studies for inclusion in the review.
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We also added the following eight reports of ongoing trials,
which we will assess for potential inclusion in the review when
data becomes available (ISRCTN79120387; NCT00931125;
NCT01091896; NCT01151722; NCT01306981;
NCT01589718a; NCT01805297 NCT01854593).
Included studies
We identified 12 completed studies from the electronic database
searches that met our inclusion criteria; see the Characteristics of
included studies table for details.
Setting and participants
The included studies were conducted in a number of countries.
Three were from Iran, two were from Italy, two were from Egypt,
and the remainingwere fromSouthKorea,USA,Mexico, Pakistan,
and Japan. The included studies randomised a total of 654 eyes.
Sample size varied from 20, in Sohn 2012, to 107, in Ahn 2011.
The mean age of the participants included was 54.2 years.
Intervention
The majority of included studies gave 1.25 mg intravitreal beva-
cizumab (IVB) (0.05 ml) within one week of pars plana vitrec-
tomy. The studies with a different protocol were the following.
• Ahn 2011 had an intervention group in which 1.25 mg
IVB was given at the end of surgery (37 participants).
• di Lauro 2009 had an intervention group that received
1.25mg IVB three weeks before vitrectomy.
• Hernández-Da Mota 2010 gave 1.25 mg IVB 48 hours
before surgery.
• Manabe 2015 gave 0.16 mg (0.05 ml) IVB one day before
surgery.
• Modarres 2009 gave 2.5 mg IVB three to five days before
surgery.
Outcomes
The main outcomes in the trials included best-corrected visual
acuity (BCVA), feasibility of surgery (operating time, intraoper-
ative bleed, and type of surgical steps required), and postopera-
tive complications. The main postoperative complications were
rate of POVCH, iris rubeosis, and retinal detachment. Follow-up
varied significantly across the trials, ranging from one month, in
Ahmadieh 2009 and Manabe 2015, to one year, in Elwan 2013.
The majority of trials had a final follow-up visit at six months.
A number of trials reporting the incidence of POVCH have in-
cluded participants who received silicone oil endotamponade,
which has made interpretation of the trial results difficult. The
presence of silicone oil within the vitreous cavity precludes an ac-
curate diagnosis of POVCH, as any blood would be localised to
the far periphery of the posterior chamber. Grading of POVCH
is not possible with silicone endotamponade present. In light of
this, we have carried out sensitivity analyses on the incidence of
POVCH excluding participants with silicone oil endotamponade.
Two trials excluded participants who received silicone oil and gave
an accurate grading system for POVCH (Ahmadieh 2009; Ahn
2011).
In addition, we identified nine ongoing RCTs and have provided
details in the Characteristics of ongoing studies table. We cannot
comment on whether the these studies’ characteristics meet the
inclusion criteria until they are published and we can undertake a
review of their methodology.
Excluded studies
We excluded 26 studies identified by the search that were either
non-randomised prospective studies or retrospective studies; see
the Characteristics of excluded studies table. We excluded two
trials that did not collect data on POVCH (da R Lucena 2009;
Pakzad-Vaezi 2014).
Risk of bias in included studies
See also Figure 2 and Figure 3.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Ahmadieh 2009 and Ahn 2011 clearly stated how the random
sequence generation was performed. In both studies, a biostatisti-
cian was used to allocate participants and ensure that investigators
were unaware of the series details. We graded the methods as ’low’
risk for randomisation and allocation. di Lauro 2009 stated that
participants were randomly assigned into the three groups, but
provided no description on how the randomisation or sequence al-
location was performed. El Batarny 2008, Elwan 2013, Farahvash
2011, Hernández-Da Mota 2010, Modarres 2009, Sohn 2012,
and Zaman 2013 did not state how participants were allocated
into each group and provided no details about the randomisa-
tion methods. Rizzo 2008 used a table of random numbers to as-
sign each study participant to group one or group two, but pro-
vided no details of the sequence generation. We graded the meth-
ods used for allocation as ’unclear’ for di Lauro 2009, El Batarny
2008, Elwan 2013, Farahvash 2011, Hernández-Da Mota 2010,
Modarres 2009, Rizzo 2008, Sohn 2012, and Zaman 2013. In
Manabe 2015, the allocation was done by the “envelop” methods,
but the generation of the allocation sequence was not clearly de-
scribed.
Blinding
We assessed Ahmadieh 2009 and Sohn 2012 as at ’low’ risk of
bias for masking (blinding), as a clear description of how this
process was performed was provided. We graded Ahn 2011, El
Batarny 2008, Elwan 2013, Farahvash 2011, and Hernández-Da
Mota 2010, which had an open-label design, as ’high’ risk. We
graded di Lauro 2009, Rizzo 2008, Modarres 2009, and Zaman
2013, which did not comment on the masking of participants or
investigators, as ’unclear’.
Incomplete outcome data
Ahmadieh 2009, Ahn 2011, Farahvash 2011, and Sohn 2012
clearly accounted for each participant who failed to complete the
study protocol. It should be noted that in Ahmadieh 2009, less
than half the participants (16 of 35) within the treatment group
failed to complete the protocol, and only 18 of 35 participants
within the control group completed the protocol. Manabe 2015
reported participant flow; all participants were followed up to 1
month. Although the remaining included RCTs did not comment
directly on the attrition rate, it is clear from the results that all
participants completed follow-up.
Selective reporting
All the included studies reported the stated primary and secondary
outcomes.
Other potential sources of bias
Ahmadieh 2009 recorded a high number of participants who failed
to complete the trial in both the control and treatment groups:
15 of 35 in the control group and 19 of 35 in the treatment
14Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative
diabetic retinopathy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
group. The main reasons for failing to complete follow-up were
vitreous haemorrhage reabsorption, silicone oil endotamponade,
gas tamponade, and lost to follow-up.
Ahn 2011 included 107 eyes of 91 participants. The 16 bilateral
participants were included in the data analysis; no comment was
made as to whether adjustment for within-person correlation was
performed during statistical analysis.
In the IVB group of Manabe 2015, participants with bilateral pro-
liferative diabetic retinopathy (PDR) received IVB in one eye only,
and the other eye was excluded from the study. The authors con-
sidered that IVB injected in one eye may pass to the contralateral
eye. In the control group, both eyes of bilateral cases were included
in the study.
Effects of interventions
See: Summary of findings for the main comparison
We have described the effect of each intervention in order of out-
come type.
Primary outcomes
1. The incidence of early POVCH after surgery
Eight included RCTs commented on the incidence of early
POVCH following pre- or intraoperative anti-VEGF administra-
tion (Ahmadieh 2009; Ahn2011; di Lauro 2009; ElBatarny 2008;
Farahvash 2011; Hernández-Da Mota 2010; Modarres 2009;
Zaman 2013). As many of the RCTs included participants who
received silicone oil endotamponade in their results, making it
difficult to establish the true incidence and grade of POVCH, we
have performed a number of sensitivity analyses for this outcome
excluding trials that included silicone oil cases. They are as follows.
• Analysis 1.1: Contained only data from Ahmadieh 2009
and Ahn 2011, as these two RCTs excluded participants who
received silicone oil and gave an accurate grading system for
POVCH. The analysis included only grade 2 POVCH or worse.
The use of pre- or intraoperative IVB was shown to reduce the
incidence of early POVCH (risk ratio (RR) 0.28, 95%
confidence interval (CI) 0.08 to 0.96). This analysis contained
144 participants, 89 in the intervention arm and 55 in the
control arm.
• Analysis 1.2: Included all trials that reported the incidence
of POVCH (all grades). The use of pre- or intraoperative IVB
was shown to reduce the incidence of POVCH (RR 0.35, 95%
CI 0.23 to 0.53; eyes = 512; studies = 9; I2 = 0%) (Figure 4).
Thirty-seven participants in the intervention group received
intraoperative IVB.
Figure 4. Forest plot of comparison: 1 Anti -VEGF vs control, outcome: 1.2 Early POVCH (all grades).
• Analysis 1.3: Included all trial results that reported the
incidence of POVCH (all grades) with participants who received
silicone oil endotamponade excluded. The use of pre- or
intraoperative IVB was shown to reduce the incidence of
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POVCH (RR 0.34, 95% CI 0.19 to 0.60; eyes = 302; studies =
6; I2 = 7%).
Sohn 2012 did comment on one case of POVCH found at three-
month follow-up in the control group. The corresponding author
could not provide a clear definition of early or late POVCH. We
have therefore not included this result within the above analyses.
2. The incidence of late POVCH after surgery
Three included studies commented on the effect of IVB on the
incidence of late POVCH (Ahn 2011: Farahvash 2011; Zaman
2013). Only Ahn 2011 gave a grade for the severity of late
POVCH. Analysis 1.4 contained the reported data from all the
trials that commented on late POVCH (any grade) and found no
reportable effect of pre- or intraoperative IVB on late POVCH
(RR 0.72, 95% CI 0.30 to 1.72). This analysis contained 196
participants, 115 in the intervention arm and 81 in the control
arm (Figure 5).
Figure 5. Forest plot of comparison: 1 Anti-VEGF versus control, outcome: 1.4 Late POVCH (all grades).
Ahn 2011 found no statistical difference between the rate of late
POVCH in the control group and combined pre- and intraoper-
ative IVB groups, P = 0.813.
Hernández-Da Mota 2010 included “recurrent haemorrhage” as
an outcome, however provided no definition. We attempted to
contact the corresponding author, but received no reply. These
data are therefore currently excluded.
Secondary outcomes
1. Visual acuity at six months following the primary
vitrectomy
Seven included studies commented on BCVA at six months or
longer (Ahn 2011; di Lauro 2009; El Batarny 2008; Elwan 2013;
Modarres 2009; Rizzo 2008; Zaman 2013). Six of the studies
used LogMAR method for measuring acuity, while Elwan 2013
reported decimal acuity. Zaman 2013 provided a comparison of
pre- and postoperative BCVA; the study provided no specific val-
ues.
We found considerable heterogeneity between studies (I2 = 88%)
with mean difference in acuity ranging from 1.31 logMAR units
better vision in the anti-VEGF group, Hernández-DaMota 2010,
to 0.14 logMAR units better vision in the control group, Ahn
2011 (Analysis 1.5) (Figure 6). This means that a pooled estimate
of effect may not be informative.
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Figure 6. Forest plot of comparison: 1 Anti -VEGF vs control, outcome: 1.5 Visual acuity at six months or
longer [logMAR].
2. The incidence of vitreous cavity washout or revision
vitrectomy at six months
Five RCTs commented on the rate of vitreous cavity washout
within six months (di Lauro 2009; El Batarny 2008; Elwan 2013;
Manabe 2015; Modarres 2009). Analysis 1.6 showed that people
receiving IVB were less likely to receive vitreous cavity washout
(RR 0.19, 95% CI 0.06 to 0.67; eyes = 291; studies = 5; I2 = 0%).
3. Adverse effects of intervention including cataract, iris
rubeosis and rubeotic glaucoma, retinal detachment,
increased inflammation and systemic side effects
We have provided all reported adverse events in detail in Table 1.
No systemic complications of IVB use were reported.
As many of the included RCTs commented on the rate of postop-
erative retinal detachment, we elected to analyse this data. We did
not list this analysis on the review protocol and undertook it at the
update stage. Analysis 1.7 showed the risk of postoperative retinal
detachment was lower within the intervention arm, but the result
was not statistically significant, the confidence intervals were wide
and include 1 (no effect) (RR 0.46, 95% CI 0.19 to 1.08). This
analysis contained 372 participants, 208 in the intervention arm
and 164 in the control arm.
4. Quality of life measures performed at least six months
following vitrectomy
There are currently no studies that comment on this outcome.
5. Density of POVCH, as measured by the Diabetic
Vitrectomy Study criteria
Ahmadieh 2009 clearly stated the grading for the density of
POVCH within the results section. Four participants had grade 2
or 3 POVCH in the treatment group at one-week follow-up (4/
16 (25%)), while 10 participants had grade 2 or 3 POVCH at
the same follow-up within the control group (10/18 (55.5%)). At
one-month follow-up this had changed to two participants within
the treatment group (2/16 (12.5%)) and nine within the control
group (9/18 (50%)).
Ahn 2011 defined POVCH in a similar manner to the Diabetic
Vitrectomy Study criteria. At one month following surgery, 2/
36 (5.6%), 0/37, and 1/34 (2.9%) of participants had grade 2
or worse POVCH in study group 1 (preoperative IVB), group 2
(intraoperative IVB), and group 3 (control), respectively.
The incidence of late POVCH (grade 2 or worse) occurred in
3/36 (8.3%) in the preoperative IVB group, 3/37 (8.1%) in the
intraoperative IVB group, and 3/34 (8.8%) in the control group.
di Lauro 2009 commented that grade 3 POVCH (no fundal view)
occurred in 6/24 (25%) of eyes in the control group and 1/24
(4%) and 2/24 (8.3%) of eyes that received bevacizumab 7 and
20 days preoperatively, respectively, when assessed three months
postoperatively.
El Batarny 2008, Farahvash 2011, Hernández-Da Mota 2010,
Modarres 2009, and Zaman 2013 did not clearly state the grading
of POVCH.
D I S C U S S I O N
Summary of main results
The aim of this review was to establish whether the use of anti-
VEGFs as an adjunct to pars plana vitrectomy, either pre- or intra-
operatively, is of benefit. Currently the review includes 12 RCTs,
all of which look at the use of IVB. The main outcomes were the
effect of IVB on early and late POVCH, BCVA, vitreous cavity
washout rates, and postoperative complications. We summarised
the effect of IVB by outcome type.
Primary outcomes
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1. The incidence of early POVCH after surgery
Nine RCTs commented on the effect of IVB on the incidence
of early POVCH. Analysis 1.1, Analysis 1.2, and Analysis 1.3 all
showed a beneficial effect of IVB in reducing the rate of early
POVCH following vitrectomy. The inclusion of participants who
received silicone oil endotamponade may well have biased the
true incidence of early POVCH, and so we advise caution when
interpreting the results of Analysis 1.2 and Analysis 1.3. However,
as silicone oil is commonly used following complex delamination
surgery, the inclusion of this group is important and may provide
a more practical guide to the effect of IVB.
2. The incidence of late POVCH after surgery (defined as
occurring more than four weeks postoperatively after a
period during which the vitreous cavity was clear)
Three RCTs reported the effect of IVB on late POVCH. Analysis
1.4 found no evidence of an effect of pre- or intraoperative IVB on
the rate of late POVCH. This analysis contained two RCTs that
included participants with silicone oil endotamponade in their
results. Again, this may bias the true incidence of late POVCH.
Ahn 2011 was the only study that excluded these participants
before reporting their results, and found no effect of IVB on late
POVCH.
Secondary outcomes
1. Visual acuity at six months following the primary
vitrectomy
The current analysis (Analysis 1.5, Figure 6) suggested that use
of IVB has no significant effect on average BCVA at six months.
However, due to substantial heterogeneity between studies, we
could not estimate an accurate pooled effect.
Many factors could affect BCVA within this heterogenous group
of participants, particularly clarity of the media and vitreous cav-
ity. The presence of silicone oil within the vitreous cavity will en-
sure it is clear in situations when potential recurrent haemorrhage
may well have caused reduced vision. Further RCTs that exclude
silicone oil participants are needed before a more accurate result
can be reported.
2. The incidence of vitreous cavity washout or revision
vitrectomy within six months
Two of the five studies within this analysis (Analysis 1.6) had no
estimable effect. The incidence of vitreous cavity washout was
reduced with the use of IVB.
3. Adverse effects of intervention including cataract, iris
rubeosis and rubeotic glaucoma, retinal detachment,
increased inflammation and systemic side effects
All included RCTs reported the adverse effects of preoperative IVB
(Table 1). The results suggested that the risk of complications and
adverse side effects appears to be small.
4. Quality of life measures performed at least six months
following vitrectomy
There are currently no studies that comment on this outcome.
5. Density of POVCH, as measured by the Diabetic
Vitrectomy Study criteria
Ahmadieh 2009, Ahn 2011, and di Lauro 2009 commented on
the density of POVCH. Five other studies that commented on the
density of POVCH did not clearly state the grading of POVCH,
and the trial authors were unable to provide further information
when contacted. We can draw no conclusion about the relative
density of POVCH using preoperative IVB compared with con-
trols.
Overall completeness and applicability of
evidence
This review included 12 trials conducted in Europe, North Amer-
ica, Africa, andAsia. The results of these trials are likely to be appli-
cable to standard clinical practice. The trials consistently showed
that IVB applied around the time of vitrectomy to reduce the
occurrence of complications of proliferative diabetic retinopathy
decreased the risk of POVCH. However, the evidence was less
complete with respect to other outcomes; for example the effect
of IVB on visual acuity and adverse effects was less certain.
All the trials used IVB and most trials used a similar dose of (1.25
mg), but a variety of regimens were used in terms of whether the
dose was given before, immediately before, or during surgery. No
data were available on other anti-VEGF agents.
A number of ongoing RCTs are currently looking at the effects
of ranibizumab, pegaptanib sodium, and aflibercept on POVCH
and BCVA (see Characteristics of ongoing studies). The results
of these trials will help clarify the effect of anti-VEGF on late
POVCH and BCVA.
Quality of the evidence
The design of RCTs looking at the effect of adjunctive use of
anti-VEGF in diabetic vitrectomy is difficult. There are a number
of indications for vitrectomy in proliferative retinopathy. These
vary from non-clearing vitreous haemorrhage in older patients
with previously treated inactive proliferative diabetic retinopathy,
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through to younger patients with active untreated proliferative
diabetic retinopathy and severe tractional changes. Many of the
includedRCTs had a heterogenous group of participants, as above,
and the effect of IVBonPOVCHandBCVAmaydiffer depending
on the patient type.
Five of the included trials appear to be or state that they are ’open
label’. This is a significant proportion and may limit confidence
in the estimation of the treatment effect of IVB.
We restricted the meta-analysis to published RCT data, and it
may be possible that bias exists if smaller trials not accepted for
publication found no effect on early POVCH. A number of the
included trials had a low number of participants, which reduces
the power of the current analysis.
Potential biases in the review process
The review authors followed the key criteria listed within the
Assessment of risk of bias in included studies section of the review
to ensure that risk of bias was minimised during trial selection.
Agreements and disagreements with other
studies or reviews
Zhao 2011 performed a systematic review looking at the potential
benefits of preoperative IVB on both intraoperative (including in-
traoperative bleeding, endodiathermy, iatrogenic retinal tears, and
mean surgical time) and postoperative (including BCVA, recur-
rent vitreous haemorrhage, reabsorption time of blood and other
complications) outcomes.
Data analysis of included studies within the Zhao 2011 review,
which looked at the incidence of early POVCH, showed an almost
statistically significant result in favour of the treatment group (odds
ratio (OR) 5.48, 95% CI 0.97 to 31.02; P = 0.05). This result
is in agreement with the data analysis of this review. However, it
should be noted that many of the included studies within the Zhao
2011 data analysis contained participants who received silicone oil
endotamponade, which may be a significant source of bias. Also,
the Zhao 2011 authors commented that due to varying definitions
of POVCH, study heterogeneity within the data analysis was high
(I2 = 93.6%), and so the results should be interpretedwith caution.
Zhang 2013 reported similar outcomes in a meta-analysis of the
reported data on preoperative IVB use in vitrectomy for prolifer-
ative diabetic retinopathy. The study reported a beneficial effect
of IVB on the rate of early POVCH (OR 0.35, 95% CI 0.21 to
0.58) and no effect on the rate of late POVCH (OR 0.55, 95%
Cl 0.25 to 1.21).
Veliz 2014 summarised the results of a previously published ver-
sion of this review. Zhang 2013, Zhao 2011, and Veliz 2014 con-
cluded that bevacizumab probably decreased intraoperative bleed-
ing, but its effect on visual acuity is uncertain. They concluded
that it might increase the risk of cardiovascular events, but this was
based on a RR of 2.2 with 95% CIs from 0.11 to 44.3, so there is
some uncertainty with this estimate as well.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review provides support for the use of perioperative IVB
to prevent POVCH after vitrectomy for proliferative diabetic
retinopathy. The current analysis suggests that pre- or intraopera-
tive IVB reduces the risk of early POVCH, but the effect on late
POVCH is uncertain. The number of reported severe complica-
tions from IVB use was low.
Implications for research
Further randomised studies looking at the effect of anti-VEGF
agents on the incidence and management of POVCH will
strengthen the current evidence base. These studies need to ad-
dress the effect on both early and late POVCH, while ensuring
that the use of endotamponade, which may be required during
the postoperative period, is clearly stated within the results and
allowed for in the power calculations prior to the study. Further-
more, the spontaneous clearance of vitreous haemorrhage or clear-
ance following the injection of an anti-VEGF should be factored
in for the power calculation. A minimum follow-up period of at
least six months is important to ensure that late POVCH can be
recognised. Visual acuity should be analysed at defined time points
andmeasured before and after further surgery to remove POVCH.
We recommend grading of POVCH using the criteria within the
Diabetic Retinopathy Vitrectomy Study, making the outcome of
RCTs more comparable and easier to subject to further analysis.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ahmadieh 2009
Methods Prospective, randomised, double-masked clinical trial
Country: Iran
Participants Number: 68 eyes of 68 participants undergoing PPV
Age: Mean (± SD) age was 55.2 ± 11.1 years (range 21 to 76 years)
Sex: 34 (50%) males; 34 (50%) females
Inclusion criteria:
1. Non-clearing vitreous haemorrhage
2. Tractional retinal detachment involving or threatening the macula
3. Active progressive PDR
Exclusion criteria:
1. BCVA of 20/40 or better
2. Pregnancy
3. History of IVB injection
4. Intraoperative use of long-acting gas or silicone oil
5. Simultaneous intraocular surgery such as cataract extraction
6. Monocular participants
Interventions Intervention:
• IVB injection (1.25 mg) 1 week before surgery (n = 35)
Comparator:
• Sham injection (n = 33)
Outcomes Primary outcome measure:
• Incidence of early (≤ 4 weeks) postoperative vitreous haemorrhage
Secondary outcome measures:
• Mean change in BCVA
• IVB-related adverse events
Follow-up: 1 day, 1 week, and 1 month after surgery
Notes Trial registration number: NCT00524875
Date study conducted: January 2007 to December 2007
Funding: not reported
Conflict of interest: reported that there were none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed by random
block permutation according to a com-
puter-generated randomisation list
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Ahmadieh 2009 (Continued)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants were masked to the treatment
method
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Visual acuity was measured by an op-
tometrist who was masked to the groups.
All pre- and postoperative examinations
were performed by one of the authors (NS)
, who was also masked to the study group
identification
Incomplete outcome data (attrition bias)
All outcomes
Low risk A flow chart included within the results
section accounted for all participants who
failed to complete the study protocol
Selective reporting (reporting bias) Low risk All primary and secondary outcomes were
reported, based on both the intention-to-
treat analysis and per-protocol analysis
Ahn 2011
Methods Prospective, randomised, open-label trial
Country: South Korea
Participants Number: 107
Age: Mean age (± SD). Preoperative IVB group 51.0 (± 9.5), intraoperative IVB group
55.6 (± 10.6), and control 55.0 (± 11.4)
Sex: (Male/female). Preoperative IVB group 23/13, intraoperative IVB group 21/16, and
control 16/18
Inclusion criteria:
1. Non-clearing vitreous haemorrhage
2. Macula-involving or macula-threatening TRD or fibrovascular proliferation with
vitreoretinal adhesions
Exclusion criteria:
1. Intraoperative use of long-acting gas or silicone oil
2. Repeat vitrectomy after first vitrectomy for retinal diseases other than vitreous
haemorrhage
3. Previous history of vitrectomy
4. Uncontrolled hypertension
5. History of blood coagulopathy
Interventions Intervention:
• IVB injection (1.25 mg/0.05 ml) 1 to 14 days before PPV
• IVB injection (1.25 mg/0.05 ml) at the end of PPV
Comparator:
• No IVB injection
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Ahn 2011 (Continued)
Outcomes Primary outcome measures:
• Incidence of early (< 4 weeks) POVCH
• Incidence of late (> 4 weeks) POVCH
Secondary outcome measures:
• Initial time of vitreous clearing
• BCVA at 6 months after surgery
Follow-up: 1 day, 1 week, 1, 3, and 6 months after surgery if there were no postoperative
events
Notes A total of 107 eyes of 91 participants, of which there were 16 bilateral participants, were
included for analysis
Trial registration number: NTC00745498
Date study conducted: June 2008 to October 2010 (from trials registry entry)
Funding: not reported
Conflict of interest: reported that there were none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was carried out using a per-
muted block analysis
Allocation concealment (selection bias) Low risk Allocation was performed by a biostatisti-
cian
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The study was open label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The study was open label
Incomplete outcome data (attrition bias)
All outcomes
Low risk The distribution and attrition rate of study
participants was clearly described in a flow
chart
Selective reporting (reporting bias) Low risk All outcomes were reported
di Lauro 2009
Methods Prospective interventional randomised controlled trial
Country: Italy
Participants Number: 72 eyes of 68 participants
Age: Not given
Sex: Not given
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di Lauro 2009 (Continued)
Inclusion criteria:
• Vitreous haemorrhage
• TRD
Exclusion criteria:
• Neovascular glaucoma or cataract, or both
• Combined traction and rhegmatogenous retinal detachment (diagnosed either
before or during the surgery)
Interventions Intervention:
• IVB injection (1.25 mg) 1 week before the vitrectomy (n = 24)
• IVB injection (1.25 mg) 3 weeks before the vitrectomy (n = 24)
Comparator:
• Sham injection: subconjunctival injection of 0.05 ml of balanced salt solution 3
weeks before the vitrectomy (n = 24)
Outcomes Primary outcome measures:
• Clearing of vitreous haemorrhage
• Incidence of adverse effects and the need for other procedures during the surgery
Secondary outcome measures:
• Change in BCVA
• Duration of surgery
Follow-up: 1, 6, 12, and 24 weeks after surgery, and ultrasonography was performed
before and 24 weeks after the injection
Notes Trial registration number: NCT01025934
Date study conducted: October 2005 to May 2007
Funding: not reported
Conflict of interest: reported that there were none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “We randomly assigned eligible patients...
” and “The patients were randomly divided
into three treatment groups (A, B, C)”
Allocation concealment (selection bias) Unclear risk Not stated in the report
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk A sham injection was used in the control
group
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk A sham injection was used in the control
group
28Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative
diabetic retinopathy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
di Lauro 2009 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Not stated in the report, however clear from
the results that all participants completed
follow-up
Selective reporting (reporting bias) Low risk Data for all main outcomes were analysed
and presented
El Batarny 2008
Methods Prospective, randomised, open-label control trial
Country: Egypt
Participants Number: 30
Age: Mean (± SD). Control group 46 (± 12) and intervention group 44 (± 11)
Sex: Not given
Inclusion criteria:
• TRD threatening or involving the macula
• TRD with vitreous haemorrhage
• Non-clearing vitreous haemorrhage (present for more than 1 month)
• Massive preretinal/subhyaloid blood covering the posterior pole
Exclusion criteria not stated
Interventions Intervention:
• IVB (1.25 mg) 5 to 7 days before surgery (n = 15)
Comparator:
• No treatment (n = 15)
Outcomes Primary outcomes:
• Feasibilty of surgery
• Postoperative complications
Follow-up: 1 day, 7 days, 2 weeks, 1 month, and then monthly until end of study (all
participants completed a minimum of 6 months)
Notes Trial registration number: not reported
Date study conducted: not reported
Funding: not reported
Conflict of interest: reported that there were none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomised by diagnosis
Allocation concealment (selection bias) Unclear risk Not stated
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El Batarny 2008 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were not masked to their study
group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Notmentioned, and treatment groupswere
different
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed follow-up
Selective reporting (reporting bias) Low risk All outcomes were reported
Elwan 2013
Methods Prospective, randomised, open-label study
Country: Egypt
Participants Number: 100
Age: Mean (± SD). Control group 61.42 (± 5.49) and intervention group 61.94 (± 5.
96)
Sex: 61 male and 39 female
Inclusion criteria:
• Complications of PDR
Exclusion criteria:
• Previous vitreoretinal surgery
• Participants with diabetes and other conditions that may cause vitreous
haemorrhage
• Diabetic participants undergoing vitrectomy for persistent macular oedema
• Participants with BCVA of less than hand movements vision
Interventions Intervention:
• IVB (1.25 mg/0.05 ml) 1 week before vitrectomy (n = 50)
Comparator:
• No IVB (n = 50)
Outcomes Primary outcomes:
• Feasibility of surgery
• Postoperative complications (postoperative vitreous haemorrhage, iris rubeosis,
and retinal detachment)
• BCVA at 12 months
Follow-up: 1 day, 1 week, 1, 3, 6, 9 months, and 1 year
Notes No response from authors to correspondence asking for clarification of POVCH defini-
tions
Trial registration number: not reported
Date study conducted: November 2008 to November 2010
Funding: not reported
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Elwan 2013 (Continued)
Conflict of interest: reported that there were none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No masking of participants
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Notmentioned, and treatment groupswere
different
Incomplete outcome data (attrition bias)
All outcomes
Low risk Nocommentwasmade.However, it is clear
from the results that all participants com-
pleted follow-up
Selective reporting (reporting bias) Low risk All outcomes were reported
Farahvash 2011
Methods Randomised, single-masked (surgeon), controlled trial
Country: Iran
Participants Number: 35
Age: Mean (range) 58.5 (37 to 73)
Sex: M/F. 18/17
Inclusion criteria:
• Vitreous haemorrhage > 1 month in a participant with no history of panretinal
photocoagulation
• Non-clearing vitreous haemorrhage in a participant with complete panretinal
photocoagulation
• Vitreous haemorrhage with neovascularisation of the iris
• Vitreous haemorrhage with glaucoma
• Vitreous haemorrhage with retinal detachment
Exclusion criteria:
• Vitrectomy or any intraocular injection in the study eye
• History of IVB in either eye
• Previous myocardial infarction or thromboembolic event
• Uncontrolled hypertension
• Use of anticoagulation (except aspirin, which was discontinued 1 week before
injection) or coagulation abnormalities
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Farahvash 2011 (Continued)
Interventions Intervention:
• IVB (1.25 mg) 7 days before surgery (n = 18)
Comparator:
• No IVB (n = 17)
Outcomes Primary outcomes:
• Severity of intraoperative bleeding and break formation
Secondary outcomes
• Visual acuity at month 3 postsurgery
• Complications of surgery: retinal detachment, neovascular glaucoma
• Early and late postoperative vitreous haemorrhage
Follow-up: 1 day, 1 week, every 3 months (minimum follow-up 3 months)
Notes We contacted the authors to further discuss the severity of POVCH in each arm of the
study. Although no formal grading scale was used to assess the POVCH, the authors
described the clinical findings as follows:
“We had two cases of early vitreous cavity haemorrhage (within 4 weeks of surgery),
both in non injection group. The haemorrhage was dense and fundus obscuring, but
resolved spontaneously during follow up. Both of them have been undergone vitrectomy
for vitreous haemorrhage without TRD, with no air, SF6 or silicone as a tamponade
We had five cases of late vitreous cavity haemorrhage before writing of paper (occurring
after more than 4 weeks), two in non injection group and three in injection group. Only
in one participant in injection group, vitreous cavity haemorrhage was dense and fundus
obscuring. In other participants, it presented as recurrent bouts of non fundus obscuring
vitreous cavity haemorrhage”
Trial registration number: not reported
Date study conducted: January 2008 to January 2009
Funding: not reported
Conflict of interest: reported that there were none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomly assigned to in-
jection of bevacizumab (injection group) or
not (control group), within each subgroup
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study participants were not masked to
which group they had been randomised to
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk All surgeons were masked regarding treat-
ment group, but it was unclear if the out-
come assessors were masked
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Farahvash 2011 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants who failed to complete the
study follow-up are clearly accounted for in
the results
Selective reporting (reporting bias) Low risk All outcomes were reported
Hernández-Da Mota 2010
Methods Prospective, randomised, open-label study
Country: Mexico
Participants Number: 40
Age: Mean 55.7 (both groups)
Sex: Not given
Inclusion criteria:
• Presence of advanced PDR
• Presence of TRD threatening the macula
• HbA1c < 7
Exclusion criteria:
• Macular involvement of retinal detachment
• Iris rubeosis
• Cataract - when precluding proper evaluation of the fundus
• No perception of light vision
• Macular ischaemia
Interventions Intervention:
• IVB (1.25 mg/0.05 ml), 48 hours before vitrectomy (n = 20)
Comparator:
• No IVB (n = 20)
Outcomes Primary outcomes:
• BCVA
• Feasibility of surgery (intraoperative bleeding, break formation)
• Postoperative complications (POVCH, iris rubeosis, and retinal detachment)
Follow-up: 1 week, 3 and 6 months
Notes No response from authors to correspondence asking for clarification of POVCH defini-
tions
Trial registration number: not reported
Date study conducted: not reported
Funding: reported none
Conflict of interest: reported that there were none
Risk of bias
Bias Authors’ judgement Support for judgement
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Hernández-Da Mota 2010 (Continued)
Random sequence generation (selection
bias)
Unclear risk “Patients were randomly assigned into two
groups”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were not masked to treatment
group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “For all patients, visual acuity and intraoc-
ular pressure were measured and recorded
before PPV in a standardized,maskedman-
ner”
However, not clearly stated whether out-
come assessment was always masked and
whether other outcomes, such as intraocu-
lar bleeding, were masked
Incomplete outcome data (attrition bias)
All outcomes
Low risk Although not directly stated, it is clear from
the results that all participants completed
the stated follow-up
Selective reporting (reporting bias) Low risk All outcomes were reported
Manabe 2015
Methods Prospective, double-masked randomised controlled trial
Country: Japan
Participants Number: 62 people (66 eyes)
Age: average 60 years (range 20 to 82)
Sex: 82% male
Inclusion criteria:
• Diagnosed as having an indication for primary vitrectomy because of persistent
vitreous haemorrhage for over 3 months and TRD caused by PDR; or fundus findings
of proliferative changes or vitreous haemorrhage in people with iris neovascularisation
or neovascular glaucoma
Exclusion criteria:
• Intraocular surgery or retinal photocoagulation within 3 months before the study
• Intravitreal injection of drugs or sub-Tenon injection of steroids within 3 months
before the study
• Cerebrovascular infarction or myocardial infarction within 3 months before the
study
Interventions Intervention:
• IVB 0.16 mg/0.05 ml) 1 day before vitrectomy (n= 32)
Comparator:
• Sham injection 1 day before vitrectomy (n=34)
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Manabe 2015 (Continued)
Outcomes Primary outcome:
• Frequency of reoperation due to postoperative recurrent vitreous haemorrhage
within 4 weeks after vitrectomy
Secondary outcome measures:
• Numbers of intraoperative laser and endodiathermy spots
• Frequency of postoperative recurrent vitreous haemorrhage within 4 weeks after
vitrectomy
• Concentration of VEGF in vitreous at the beginning of surgery
Notes Trial registration number: NCT01854593
Date study conducted: June 2012 to August 2013
Funding: not reported
Conflict of interest: reported “none”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk “...were randomised using the envelop
method”
“Both the investigators and patients were
masked to the treatment assignment”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Both the investigators and patients were
masked to the treatment assignment”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “All postoperative examinations were per-
formed by three vitreoretinal surgeons (H.
S., T.H., H.N.) who also were masked to
the study group allocation”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were followed
up for 1 month
Selective reporting (reporting bias) Low risk All outcomes on trial registry entry re-
ported
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Modarres 2009
Methods Prospective, single-masked (surgeon), randomised clinical trial
Country: Iran
Participants Number: 40
Age: Mean (± SD). Intervention group 55.8 (± 11.3) and control group 53.2 (± 11.7)
Sex: Not given
Inclusion criteria:
• Diabetics who were candidates for vitrectomy
Exclusion criteria:
• Presence of significant cataract to cause impairment of vision
• Previous IVB injection
• Other vitreoretinal pathology: past history of uveitis, retinal artery or vein
occlusion
Follow-up: Mean follow-up 7 ± 3.6 months
Interventions Intervention:
• IVB injection (2.5 mg) 3 to 5 days before operation (n = 22)
Comparator:
• No treatment (n = 18)
Outcomes Primary outcome measure:
• Facilitation of surgery and decrease in complications
Secondary outcome measure:
• Anatomic and visual outcomes at 6 months
Follow-up: Mean follow-up 7 ± 3.6 months
Notes Trial registration number: not reported
Date study conducted: not reported
Funding: not reported
Conflict of interest: reported that there were none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “40 eyes of 40 diabetic participants who
were candidates for vitrectomy were ran-
domly assigned to receive ...”
Allocation concealment (selection bias) Unclear risk Not stated in report
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated in report
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “The surgeons were masked as to the injec-
tion”, but not clear if the outcome assessors
were masked
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Modarres 2009 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Not stated in report, however clear from
the results that all participants completed
follow-up
Selective reporting (reporting bias) Low risk All data discussed within the primary out-
come for facilitation of surgery were anal-
ysed
Rizzo 2008
Methods Interventional, consecutive, randomised, prospective study
Country: Italy
Participants Number: 22
Age: Mean (range). 52 years (24 to 63)
Sex: Not given
Inclusion criteria:
• TRD
• Tractional rhegmatogenous retinal detachment
• TRD complicated by vitreous haemorrhage
Exclusion criteria:
• History of vitrectomy
• History of thromboembolic events
• Major surgery in the 3 previous months or planned within 28 days
• Uncontrolled hypertension
• Known coagulation abnormalities or current use of anticoagulative medication
other than aspirin
Interventions Intervention:
• IVB (1.25 mg) 5 to 7 days before PPV (n = 11)
Comparator:
• No IVB (n = 22)
Outcomes Primary outcome measure:
• Feasibility of the surgery
Secondary outcome measure:
• Visual and anatomic outcome at 6 months
Follow-up: up to 6 months
Notes Trial registration number: not reported
Date study conducted: not reported
Funding: not reported
Conflict of interest: reported that there were none
Risk of bias
Bias Authors’ judgement Support for judgement
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Rizzo 2008 (Continued)
Random sequence generation (selection
bias)
Low risk “We used a table of random numbers in
order to assign each study participant to
group 1 or 2”
Allocation concealment (selection bias) Unclear risk Not stated in report
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated in report
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated in report
Incomplete outcome data (attrition bias)
All outcomes
Low risk Not stated in report, however it is clear
from the results that all participants com-
pleted follow-up
Selective reporting (reporting bias) Unclear risk Results for the feasibility of surgery were
stated, but no analysis was performed
Sohn 2012
Methods Prospective, double-masked, interventional study
Country: USA
Participants Number: 20 eyes of 19 participants
Age: Median 52 years
Sex: M/F. 12/7
Inclusion criteria:
• TRD involving the macula
• Combined tractional/rhegmatogenous detachments
• Non-clearing or recurrent vitreous haemorrhage precluding panretinal
photocoagulation, with tractional detachment not involving the macula
Exclusion criteria:
• History of vitrectomy
• Dense vitreous haemorrhage preventing preoperative grading of fibrovascular
membranes
• Inability to return for PPV within 3 to 7 days after randomisation
• History of stroke, thromboembolic event, or myocardial infarction within 6
months
• Younger than 18 years
• Pregnancy
Interventions Intervention:
• IVB (1.25 mg/0.05 ml) 3 to 7 days before vitrectomy (n = 10)
Comparator:
• No treatment (n = 10)
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Sohn 2012 (Continued)
Outcomes Clinical outcomes:
• Median Visual acuity at 3 months postsurgery
• Surgical complications: POVCH, cataract, neovascular glaucoma, and retinal
detachment
Follow-up: up to 3 months
Notes We contacted the corresponding author to clarify if the POVCH was early or late. The
author confirmed that the haemorrhage had occurred in the 3-month follow-up, but
could not give more detail of when it occurred
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated in report
Allocation concealment (selection bias) Unclear risk Not stated in report
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants in the control group under-
went a sham injection
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants in the control group under-
went a sham injection
Incomplete outcome data (attrition bias)
All outcomes
Low risk The number of participants lost to follow-
up was clearly stated
Selective reporting (reporting bias) Low risk All outcomes were reported
Zaman 2013
Methods Randomised, open-label, controlled trial
Country: Pakistan
Participants Number: 54
Age: Mean (± SD). 52.07 (± 5.54). Range 39 to 67
Sex: M/F. 32/22
Inclusion criteria:
• Non-clearing vitreous haemorrhage of at least 1 month
• TRD involving or threatening the macula
• Pre-retinal subhyaloid bleeding covering the macula
Exclusion criteria: not stated
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Zaman 2013 (Continued)
Interventions Intervention:
• IVB (1.25 mg/0.05 ml) 1 week prior to surgery (n = 24)
Comparator:
• No treatment (n = 30)
Outcomes Primary outcome measures:
• BCVA after surgery
• Postoperative complications, including rate of early and late POVCH, frequency
of hyphaema and rubeosis
Follow-up: days 1, 7, 14 and then monthly for up to 6 months
Notes We attempted to contact the corresponding author to clarify details in the methodology
and results, but have received no response
Trial registration number: not reported
Date study conducted: September 2010 to August 2011
Funding: not reported
Conflict of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomised into two cate-
gories”
Allocation concealment (selection bias) Unclear risk Not commented on within the article
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Although no specific comment was made,
the study appears to be open label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Although no specific comment was made,
the study appears to be open label
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study pro-
tocol
Selective reporting (reporting bias) Low risk All stated outcomes were presented in the
results
BCVA: best-corrected visual acuity
IVB: intravitreal bevacizumab
PDR: proliferative diabetic retinopathy
PPV: pars plana vitrectomy
SD: standard deviation
TRD: tractional retinal detachment
VEGF: vascular endothelial growth factor
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdelhakim 2011 This prospective case series included 20 eyes and found the following results:
• Mean pre-injection BCVA (logMAR) was 1.460 +/- 0.439.
• Mean BCVA on day 1, week 1, months 2 and 3 after surgery were 1.645 +/- 0.422, 1.300 +/- 0.413, 1.
065 +/- 0.538, and 1.065 +/- 0.538 logMAR, respectively (P = 0.078, 0.123, 0.002, and 0.002, respectively).
• Intraoperative bleedings were minimal in most cases (85%, n = 17).
• Postoperatively, 16 participants had no bleeding (80%), 4 had minimal bleeding (20%), and 1 had
recurrent fibrovascular proliferation (5%).
The study was excluded as it was non-randomised
Berk Ergun 2014 This study was excluded as it is retrospective
Bhavsar 2014 Vitrectomy was an outcome rather than an intervention
Cheema 2010 This study was excluded as it is retrospective
da R Lucena 2009 Did not assess POVCH
Demir 2013 This study was excluded as it is retrospective
Doganay 2010 This prospective case-controlled study was excluded due to lack of randomisation. Participants were divided
into two groups: Group 1 (n = 32) received 1.25 mg of IVB 1 week before surgery; Group 2 (n = 50) did not
Results:
• Recurrent vitreous haemorrhage was found in 4 participants (12.5%) from Group 1 and in 14
participants (28%) from Group 2.
• An increase in the mean BCVA value was determined in 24 participants (75%) from Group 1 and in 32
participants (64%) from Group 2.
Goncu 2014 Excluded as not randomised.
Gupta 2008 Excluded as not randomised.
Gupta 2012a This study was excluded due to its retrospective design
Gupta 2012b Excluded as this is a retrospective observational study
Ishikawa 2009 This study was excluded because of small numbers and no control group. Also no comment made on POVCH
Jirawison 2012 Excluded as this is a retrospective observational study
Li 2010 This study was excluded due to its retrospective design
Lo 2009 This study was excluded due to its retrospective design
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(Continued)
NCT01589718 Withdrawn prior to enrolment.
Oshima 2009 This study was excluded because of the retrospective enrolment of participants, the absence of randomisation,
and the different study periods of the two groups
Pakzad-Vaezi 2014 Did not assess POVCH
Park 2010 This study was excluded due to its retrospective design
Pokroy 2011 This study was excluded due to its retrospective design
Romano 2009a Found the following results:
• No reduction in the rate of early grade 2 and 3 POVCH (2/32 (6%) at 7 days and 1 month) following
preoperative bevacizumab.
• Rates of late POVCH (grade 2 and 3): 2/32 (6%) at 3 months and 3/32 (9%) at 6 months.
• A significant improvement in 29/32 eyes (mean BCVA 1.6 (SD 1.2) to 0.4 (SD 0.8) logMAR, P = 0.02)
with surgery. There was no improvement secondary to POVCH (grade 2 to 3) in the remaining 3 eyes.
• No clinically significant intraocular inflammation on the first postoperative day. Cataract formation
occurred in 12/22 (54%).
• The incidence of grade 2 and 3 POVCH at 1 day, 1 week, 1, 3, and 6 months was 9%, 6%, 6%, 6%,
and 9%, respectively (n = 32).
This prospective study was excluded due to the lack of a control group. Participants also received an additional
dose of bevacizumab at the end of surgery, which makes interpretation of the effect of the preoperative beva-
cizumab on POVCH difficult
Romano 2009b Found the following results:
• The incidence of grade 2 and 3 POVCH in the initial postoperative period was 4/30 (14%) at 7 days
and 11/30 (36%) at 1 month.
• Rates of late POVCH (grade 2 and 3) were 9/30 (30%) at 3 and 6 months.
• Visual improvement in 21/30 treated eyes (mean BCVA 1.00 (SD 0.9) to 0.4 logMAR). There was no
improvement secondary to POVCH in the remaining eyes (9/30, P = 0.2).
• No clinically significant intraocular inflammation on the first postoperative day. Cataract formation
occurred in 9/22 (40%) of phakic participants during the 6-month follow-up.
• The incidence of grade 2 and 3 POVCH to be 20%, 14%, 36%, 30%, and 30% (n = 30).
This prospective study was excluded due to the lack of a control group
Sato 2013 This study was excluded due to its retrospective design
Yang 2008 Found the following results:
• A significant reduction in the vitreous clear-up rate postoperatively in participants who received
preoperative bevacizumab and C3F8 endotamponade, when compared with their historical control group (7.2
(SD 5.6) vs 15.2 (SD 11.4) days (P = 0.04)). No significant reduction in the rate of early POVCH (defined as
recurrent haemorrhage that obscured the retinal vessels - grade 2 or above in the Diabetic Retinopathy
Vitrectomy Study, for more than 1 week after vitreous clear-up) was observed between the treatment and
control groups (0/16 vs 1/24 (P = 0.41)).
• The rate of late POVCH in participants who received preoperative bevacizumab and C3F8
endotamponade was 1/16 (6.25%) and in the historical control group 1/24 (4%).
This study was excluded due to the small numbers and lack of randomisation (participants in the control group
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(Continued)
were selected retrospectively). Also C3F8 was used in addition to preoperative anti-VEGF in all participants in
the treatment group
Yeh 2009 Excluded as participants allocated by alternation
Yeoh 2008 Found the following results:
• No significant reduction in the overall rate of POVCH (7/18 (38.8%)), in 18 cases treated with 1.25 mg
of bevacizumab within 2 weeks of surgery. When the results are divided into early and late POVCH, 2/18
cases had early POVCH (11.1%) and 5/18 had late POVCH (27.7%).
• A late rebleed rate of 27.7% (5/18). The authors suggested that this rate may be secondary to later
reperfusion of fibrovascular tufts, once the effect of bevacizumab has worn off, which would not have been
apparent at the time of surgery.
• Visual acuity had improved in 14/18 treated eyes, was unchanged in 1/18, and was worse in 3/18. The
mean improvement in postoperative visual acuity was not quantified because of the significant number of
participants with hand movement vision preoperatively. Of the 3 participants who had reduced visual acuity, 2
had extensive macular ischaemia on fluorescein angiography, and the remaining eye still contained silicone oil.
• 7/18 (38.8%) treated eyes had POVCH within the 6-month follow-up. 6 of the 7 eyes required surgical
washout (6/18 (33.3%)).
• No adverse events in any participant treated with bevacizumab, local or systemic.
This study was excluded due to the lack of a control group.
Yeung 2010 This study was excluded as it is retrospective.
BCVA: best-corrected visual acuity
logMAR: logarithm of minimal angle of resolution
POVCH: postoperative vitreous cavity haemorrhage
SD: standard deviation
VEGF: vascular endothelial growth factor
Characteristics of ongoing studies [ordered by study ID]
ISRCTN79120387
Trial name or title A randomised, single-masked, phase IV pilot study of the efficacy and safety of adjunctive intravitreal Avastin®
(bevacizumab) in the prevention of early postoperative vitreous haemorrhage following diabetic vitrectomy
Methods Randomised, single-masked, controlled trial
Participants 30
Interventions Avastin® will be administered intravitreally in a single- or dual-dose regimen of 1.25 mg (in 0.05 ml) 2 weeks
prior to vitrectomy and at the end of vitrectomy if internal tamponade (oil, air, or gas) was not used. No
sham intravitreal injections will be given before or after vitrectomy if participant is randomised to the usual
treatment group
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ISRCTN79120387 (Continued)
Outcomes Primary:
Postoperative vitreous haemorrhage based on 2 masked clinical assessments at 6 weeks and 6 months
Secondary:
1. Recruitment and drop-out rates
2. Rates of re-operation for recurrent vitreous haemorrhage
3. Rate of postoperative rubeosis and rubeotic glaucoma
4. Rate and severity of intraoperative bleed
5. Mean change in ETDRS acuity and MNRead acuity
6. Serum Avastin® and growth factor levels at 2 and 4 to 6 weeks after injection. Vitreous levels at 2
weeks after injection
Starting date 2007
Contact information Mr Lyndon da Cruz
Moorfields Eye Hospital, 162 City Road, London
Notes No reply from lead investigator
NCT00516464
Trial name or title Evaluation of ranibizumab on the ease of procedure and complication rate in proliferative diabetic retinopathy
(PDR) requiring vitrectomy
Methods Randomised, single-masked, controlled trial
Participants 40
Interventions 40 participants will be enrolled and randomised 3:1 to ranibizumab or vitrectomy alone. 30 consented,
enrolled participants will receive 3 intravitreal injections of 0.5 mg ranibizumab administered 1 to 3 weeks
pre-procedure, intraoperatively, and 1 month postvitrectomy
Outcomes To evaluate the effect of ranibizumab on vitrectomy complications such as recurrent vitreous haemorrhage,
postoperative retinal detachment rates, and development of intraoperative retinal breaks. (Time frame: 6
months)
Starting date August 2007
Contact information Retina Associates, PA. Shawnee Mission, Kansas, United States, 66204
Contact: Lexie Manning 913-831-7400
lmanning@kcretina.com
Notes Principal Investigator: Gregory M Fox, MD. Contacted: Lead author clarified that they are unlikely to have
any data relevant to this review and will probably not go on to publish data from this trial
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NCT00931125
Trial name or title Randomized, double blinded, controlled, two-center study assessing the safety and efficacy of intravitreal
ranibizumab as a preoperative adjunct treatment before vitrectomy surgery in proliferative diabetic retinopathy
(PDR) compared to vitrectomy alone
Methods Randomised, double-masked, controlled trial
Participants Active, not recruiting. Estimate 70
Interventions This is a randomised, double-masked, controlled, 2-centre study assessing the feasibility, efficacy, and safety
of intravitreal ranibizumab injection applied as a preoperative adjunct treatment before vitrectomy surgery
in severe PDR. Comparator arm consists of participants receiving standard vitrectomy alone with sham
intravitreal injection preoperatively
Outcomes Primary outcome measures:
1. Efficacy of preoperative intravitreal ranibizumab [ Time Frame: OP day ] [ Designated as safety issue:
No ]
2. Efficacy, measured by surgical time, number of intraoperative bleedings, intraoperative retinal breaks,
required endodiathermy
Secondary outcome measures:
1. Change in BCVA [ Time Frame: 6 months ] [ Designated as safety issue: No ]
2. Effect in anatomical changes [ Time Frame: 3 ± 1 days after injection ] [ Designated as safety issue: No ]
3. Safety [ Time Frame: Over 6 months ] [ Designated as safety issue: Yes ]
4. Retinal circulation integrity [ Time Frame: Month 1, 3, 6 ] [ Designated as safety issue: Yes ].
Evaluating the circulation of original retinal vessels, evaluating the size of proliferative vessels (size of leaking
areas and number of leaking points measured by fluorescein angiography)
Starting date March 2009
Estimated study completion date: December 2013
Contact information University of Debrecen, Medical and Health Science Center, Faculty of Medicine, Department of Ophthal-
mology
Notes Debrecen, Hungary, H-4012
NCT01091896
Trial name or title Adjuvant intravitreal bevacizumab in pars plana vitrectomy for vitreous hemorrhage secondary to diabetic
retinopathy
Methods Randomised, single-masked, controlled trial
Participants Not stated
Interventions No intervention: 1 - no bevacizumab. Participants will neither receive bevacizumab before nor during vitrec-
tomy
Experimental: 2 - bevacizumab before vitrectomy. Participants will receive intravitreal injection of 1.25 mg
of bevacizumab (0.05 ml) 7 days before vitrectomy
Experimental: 3 - bevacizumab after vitrectomy. Participants will receive intravitreal injection of 1.25 mg of
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NCT01091896 (Continued)
bevacizumab (0.05 ml) at the end of vitrectomy
Outcomes Primary outcome measure: recurrent vitreous haemorrhage incidence after vitrectomy
Secondary outcome measure: visual outcome
Starting date 2010
Estimated study completion date: March 2011
Contact information felipeppalmeida@yahoo.com.br
Notes Principal Investigator: Felipe Almeida
NCT01151722
Trial name or title Adjuvant intravitreal bevacizumab in pars plana vitrectomy for diabetic vitreous hemorrhage (ABeVi)
Methods Randomised, single-masked, controlled trial
Participants Not stated
Interventions No intervention: no injection, no bevacizumab
Experimental 2: bevacizumab before vitrectomy
Experimental 3: bevacizumab after vitrectomy
Outcomes Primary outcome measure: vitreous haemorrhage recurrence [ Time Frame: 3 months ]
Starting date 2009
Estimated study completion date: December 2009
Contact information felipeppalmeida@yahoo.com.br
Notes Principal Investigator: Felipe Almeida, MD
NCT01306981
Trial name or title A prospective, randomised controlled trial of ranibizumab pre-treatment in diabetic vitrectomy - a pilot study
Methods Randomised, double-masked, controlled study
Participants Not stated
Interventions Participants will be randomised 1:1 to receive either ranibizumab intravitreal injection (0.5 mg in 0.05 ml)
or saline subconjunctival injection at the time of surgery
Outcomes Primary outcome measures:
BCVA [ Time Frame: 12 weeks post-op ]
Secondary outcome measures:
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NCT01306981 (Continued)
1. Ease of performing vitrectomy surgery
2. Incidence of postoperative vitreous haemorrhage [ Time Frame: 6 weeks post-op ]
3. Extent of retinal neovascularisation [ Time Frame: 6 weeks post-op ]
4. Extent of tractional retinal detachment [ Time Frame: 1 week postinjection ]
5. Extent of macular perfusion [ Time Frame: 12 weeks post-op ]
6. Vitreous and serum levels of ranibizumab and related cytokines [ Time Frame: 1 week postinjection ]
7. Incidence of postoperative vitreous haemorrhage [ Time Frame: 12 weeks post-op ]
8. Extent of retinal neovascularisation [ Time Frame: 12 weeks post-op ]
Starting date 2011
Estimated study completion date: March 2013
Contact information Moorfields Eye Hospital NHS Foundation Trust
Notes Principal Investigator: Mr James W Bainbridge MA, PhD, FRCOphth. Contacted: Currently the study is in
the write-up stages. Unpublished data on the rate of POVCH are as follows:
Vitreous cavity haemorrhage occurred in 4/15 in the ranibizumab (Lucentis®) arm and 6/15 in the control
arm.
At 12-weeks post-op persistent vitreous cavity haemorrhage was observed in 0/15 in the ranibizumab arm
and 2/15 in the control arm
NCT01805297
Trial name or title Intravitreal aflibercept injection as a surgical adjuvant in severe proliferative diabetic retinopathy
Methods Randomised, open-label, controlled trial
Participants 12
Interventions 1. Vitrectomy with Aflibercept Injection Preoperative 2.0 mg intravitreal aflibercept and vitrectomy with
intraoperative 2.0 mg intravitreal aflibercept injection
2. Standard Vitrectomy Preoperative 2.0 mg intravitreal aflibercept and standard of care vitrectomy
Outcomes Primary outcome measures:
1. Rate of postoperative vitreous haemorrhage [ Time Frame: 24 weeks ]
2. Amount of postoperative vitreous haemorrhage [ Time Frame: 24 weeks ]
Secondary outcome measures:
1. Mean change in visual acuity [ Time Frame: 24 weeks ]
2. Need for any additional surgical intervention [ Time Frame: 24 weeks ]
3. Changes in mean central retinal thickness [ Time Frame: 24 weeks ]
4. Changes in mean PDR grading [ Time Frame: 24 weeks ]
Starting date 2013
Estimated study completion date: April 2014
Contact information Robert-Leonard@dmei.org
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NCT01805297 (Continued)
Notes Principal Investigator: Robert Leonard MD
NCT01854593
Trial name or title Prospective randomized controlled study on the efficacy of 0.16 mg intravitreal bevacizumab injection for
proliferative diabetic retinopathy
Methods Randomised, double-masked, controlled trial
Participants 66 (recruitment completed August 2013)
Interventions Control group: sham injection and 25 gauge vitrectomy
Intervention group: 0.16 mg/0.05 ml bevacizumab (single injection 1 day before operation) and 25 gauge
vitrectomy
Outcomes 1. VEGF concentration in vitreous after intravitreal bevacizumab injection [ Time Frame: 1 year ]
2. Early (within 4 weeks) postoperative vitreous haemorrhage
3. Re-operation due to vitreous haemorrhage
Starting date May 2012
Contact information Ayumu Manabe, Nihon University
Notes Study results on ClinicalTrials.gov
BCVA: Best-corrected visual acuity
ETDRS: Early Treatment Diabetic Retinopathy Study
PDR: proliferative diabetic retinopathy
TRD: tractional retinal detachment
VEGF: vascular endothelial growth factor
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D A T A A N D A N A L Y S E S
Comparison 1. Anti-VEGF versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Early POVCH (grade 2 or
worse)
2 144 Risk Ratio (M-H, Fixed, 95% CI) 0.28 [0.08, 0.96]
2 Early POVCH (all grades) 9 512 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.23, 0.53]
3 Early POVCH (all grades,
excluding silicone oil cases)
6 302 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.19, 0.60]
4 Late POVCH (all grades) 3 196 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.30, 1.72]
5 Visual acuity at six months or
longer
5 Mean Difference (IV, Random, 95% CI) Totals not selected
6 Vitreous cavity washout 5 291 Risk Ratio (M-H, Random, 95% CI) 0.19 [0.06, 0.67]
7 Retinal detachment 7 372 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.19, 1.08]
Analysis 1.1. Comparison 1 Anti-VEGF versus control, Outcome 1 Early POVCH (grade 2 or worse).
Review: Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy
Comparison: 1 Anti-VEGF versus control
Outcome: 1 Early POVCH (grade 2 or worse)
Study or subgroup Anti VEGF Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ahmadieh 2009 (1) 2/16 9/18 86.5 % 0.25 [ 0.06, 0.99 ]
Ahn 2011 (2) 1/73 1/37 13.5 % 0.51 [ 0.03, 7.88 ]
Total (95% CI) 89 55 100.0 % 0.28 [ 0.08, 0.96 ]
Total events: 3 (Anti VEGF), 10 (Control)
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.02 (P = 0.044)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Anti VEGF Favours Control
(1) Data included from this paper is the ’per protocol’ outcomes
(2) Data in the experimental group includes both pre-operative and intraoperative administration of bevacizumab
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Analysis 1.2. Comparison 1 Anti-VEGF versus control, Outcome 2 Early POVCH (all grades).
Review: Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy
Comparison: 1 Anti-VEGF versus control
Outcome: 2 Early POVCH (all grades)
Study or subgroup Anti-VEGF Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ahmadieh 2009 (1) 5/35 13/33 21.4 % 0.36 [ 0.15, 0.91 ]
Ahn 2011 (2) 12/73 11/34 35.5 % 0.51 [ 0.25, 1.03 ]
di Lauro 2009 (3) 3/48 6/24 10.7 % 0.25 [ 0.07, 0.91 ]
El Batarny 2008 0/15 4/15 2.2 % 0.11 [ 0.01, 1.90 ]
Farahvash 2011 (4) 0/18 2/17 2.0 % 0.19 [ 0.01, 3.68 ]
Hern ndez-Da Mota 2010 4/20 8/20 16.9 % 0.50 [ 0.18, 1.40 ]
Manabe 2015 1/32 8/34 4.4 % 0.13 [ 0.02, 1.00 ]
Modarres 2009 0/22 7/18 2.3 % 0.06 [ 0.00, 0.90 ]
Zaman 2013 (5) 1/24 11/30 4.6 % 0.11 [ 0.02, 0.82 ]
Total (95% CI) 287 225 100.0 % 0.35 [ 0.23, 0.53 ]
Total events: 26 (Anti-VEGF), 70 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.19, df = 8 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 4.91 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours anti-VEGF Favours control
(1) 1.25mg IVB one week before surgery; follow-up 4 weeks after surgery
(2) 1.25mg IVB one day to two weeks before surgery or during surgery; follow-up 4 weeks after surgery
(3) 1.25mg IVB one week or three weeks before surgery; follow-up 4 weeks after surgery
(4) Note from JE: could not find these data in paper: 1.25mg IVB one week before surgery; follow-up 4 weeks after surgery
(5) 1.25mg IVB one week before surgery; follow-up 4 weeks after surgery
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Analysis 1.3. Comparison 1 Anti-VEGF versus control, Outcome 3 Early POVCH (all grades, excluding
silicone oil cases).
Review: Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy
Comparison: 1 Anti-VEGF versus control
Outcome: 3 Early POVCH (all grades, excluding silicone oil cases)
Study or subgroup Anti VEGF Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ahmadieh 2009 5/35 13/33 32.3 % 0.36 [ 0.15, 0.91 ]
Ahn 2011 12/73 11/34 48.6 % 0.51 [ 0.25, 1.03 ]
El Batarny 2008 0/12 4/6 4.1 % 0.06 [ 0.00, 0.96 ]
Farahvash 2011 0/15 2/15 3.6 % 0.20 [ 0.01, 3.85 ]
Manabe 2015 1/28 6/28 7.3 % 0.17 [ 0.02, 1.30 ]
Modarres 2009 0/12 7/11 4.1 % 0.06 [ 0.00, 0.97 ]
Total (95% CI) 175 127 100.0 % 0.34 [ 0.19, 0.60 ]
Total events: 18 (Anti VEGF), 43 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 5.37, df = 5 (P = 0.37); I2 =7%
Test for overall effect: Z = 3.72 (P = 0.00020)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Anti VEGF Favours Control
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Analysis 1.4. Comparison 1 Anti-VEGF versus control, Outcome 4 Late POVCH (all grades).
Review: Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy
Comparison: 1 Anti-VEGF versus control
Outcome: 4 Late POVCH (all grades)
Study or subgroup Anti-VEGF Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ahn 2011 10/73 5/34 48.6 % 0.93 [ 0.34, 2.52 ]
Farahvash 2011 3/18 2/17 22.7 % 1.42 [ 0.27, 7.46 ]
Zaman 2013 2/24 9/30 28.7 % 0.28 [ 0.07, 1.17 ]
Total (95% CI) 115 81 100.0 % 0.72 [ 0.30, 1.72 ]
Total events: 15 (Anti-VEGF), 16 (Control)
Heterogeneity: Tau2 = 0.15; Chi2 = 2.63, df = 2 (P = 0.27); I2 =24%
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours anti-VEGF Favours control
Analysis 1.5. Comparison 1 Anti-VEGF versus control, Outcome 5 Visual acuity at six months or longer.
Review: Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy
Comparison: 1 Anti-VEGF versus control
Outcome: 5 Visual acuity at six months or longer
Study or subgroup Anti-VEGF Control
Mean
Difference
Mean
Difference
N Mean(SD)[logMAR] N Mean(SD)[logMAR] IV,Random,95% CI IV,Random,95% CI
Ahn 2011 (1) 73 0.6504 (0.5243) 34 0.51 (0.56) 0.14 [ -0.08, 0.36 ]
di Lauro 2009 (2) 48 0.84 (1.0944) 24 1.2 (1.4) -0.36 [ -1.00, 0.28 ]
El Batarny 2008 (3) 15 0.75 (0.68) 15 0.91 (0.67) -0.16 [ -0.64, 0.32 ]
Hern ndez-Da Mota 2010 (4) 20 0.76 (0.6395) 20 2.07 (0.8139) -1.31 [ -1.76, -0.86 ]
Modarres 2009 (5) 22 1.1 (0.4) 18 1.4 (0.3) -0.30 [ -0.52, -0.08 ]
-10 -5 0 5 10
Favours anti-VEGF Favours control
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(1) Follow-up: 6 months
(2) Follow-up: 6 months
(3) Follow-up: 12 months (range 7-18 months)
(4) Follow up: 6 months
(5) Follow-up: 6 months
Analysis 1.6. Comparison 1 Anti-VEGF versus control, Outcome 6 Vitreous cavity washout.
Review: Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy
Comparison: 1 Anti-VEGF versus control
Outcome: 6 Vitreous cavity washout
Study or subgroup Anti-VEGF Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
di Lauro 2009 1/48 2/24 28.0 % 0.25 [ 0.02, 2.62 ]
El Batarny 2008 0/15 0/15 Not estimable
Elwan 2013 1/50 5/50 34.7 % 0.20 [ 0.02, 1.65 ]
Manabe 2015 1/32 7/34 37.2 % 0.15 [ 0.02, 1.17 ]
Modarres 2009 0/12 0/11 Not estimable
Total (95% CI) 157 134 100.0 % 0.19 [ 0.06, 0.67 ]
Total events: 3 (Anti-VEGF), 14 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 2 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 2.60 (P = 0.0094)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours anti-VEGF Favours control
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Analysis 1.7. Comparison 1 Anti-VEGF versus control, Outcome 7 Retinal detachment.
Review: Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy
Comparison: 1 Anti-VEGF versus control
Outcome: 7 Retinal detachment
Study or subgroup Anti-VEGF Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ahn 2011 0/73 1/34 7.3 % 0.16 [ 0.01, 3.77 ]
El Batarny 2008 1/15 2/15 14.0 % 0.50 [ 0.05, 4.94 ]
Elwan 2013 3/50 6/50 41.7 % 0.50 [ 0.13, 1.89 ]
Farahvash 2011 1/18 1/17 10.2 % 0.94 [ 0.06, 13.93 ]
Hern ndez-Da Mota 2010 1/20 4/20 16.7 % 0.25 [ 0.03, 2.05 ]
Modarres 2009 1/22 1/18 10.1 % 0.82 [ 0.05, 12.19 ]
Sohn 2012 0/10 0/10 Not estimable
Total (95% CI) 208 164 100.0 % 0.46 [ 0.19, 1.08 ]
Total events: 7 (Anti-VEGF), 15 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.23, df = 5 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.78 (P = 0.075)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours anti-VEGF Favours control
A D D I T I O N A L T A B L E S
Table 1. Adverse effects
Adverse ef-
fect
Injection-
re-
lated com-
plications
Raised
intraocular
pressure
Iris neovas-
cularisation
Neovas-
cular glau-
coma
Cataract
progression
Retinal de-
tachment
Systemic
adverse ef-
fects
Other local
effects
Study
Ahmadieh
2009
No cases 1 person
only
No cases - - - - -
Ahn 2011 - - - Anti-
VEGF: 5/73
(7%) Con-
trol:
1/34 (3%)
Anti-VEGF:
5/60 (8%)
Control:
5/32 (16%)
Anti-VEGF:
0/73 (0%)
Control:
1/34 (3%)
No cases -
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Table 1. Adverse effects (Continued)
di Lauro
2009
- - - - - 3/72 (4%)
but unclear
which group
No cases -
El Batarny
2008
- - Anti-VEGF:
0/20
Control:
1/15 (6.7%)
- Anti-VEGF:
4/15 (26.
6%)
Control:
7/15 (46.
7%)
Anti-VEGF:
1/15 (6.7%)
Control:
2/15 (13.
3%)
No cases -
Elwan 2013 - - Anti-VEGF:
Regressed in
10/50
(20%)
Control:
Persisted in
6/50 (12%)
No
new post-op
cases
reported
- - Anti-VEGF:
3/50 (6%)
Control: 6/
50 (12%)
No cases -
Farahvash
2011
- - No cases No cases “During the
follow-
up, all but 2
pha-
kic patients
with signifi-
cant cataract
and best-
corrected vi-
sual acuity <
20/200 un-
derwent
cataract
surgery”
Anti-VEGF:
1/18 (6%)
Control:
1/17 (6%)
Mortality
(range 3-15
months fol-
low-up)
Anti-VEGF:
1/18 (6%)
Control:
1/17 (6%)
-
Hernandez-
Da Mota
2010
- Anti-VEGF:
4/20 (20%)
Control:
0/20
- Anti-VEGF:
0/20
Control:
2/20 (10%)
Anti-VEGF:
3/20 (15%)
Control:
4/20 (20%)
Anti-VEGF:
1/20 (5%)
Control:
4/20 (20%)
- -
Manabe
2015
No cases Anti-VEGF:
2/32 (6%)
Control:
6/34 (18%)
- Anti-VEGF:
0/32
Control:
3/34 (9%)
- - No cases -
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Table 1. Adverse effects (Continued)
Modarres
2009
- - - - - Anti-VEGF:
1/22 (5%)
Control:
1/18 (6%)
No cases No cases
Sohn 2012 - - - Anti-VEGF:
0/10
Control:
1/10 (10%)
Anti-VEGF:
1/10 (10%)
Control:
1/10 (10%)
No cases - -
Zaman
2013
- - Anti-VEGF:
3/24 (13%)
Control:
7/30 (23%)
- - - - -
VEGF: vascular endothelial growth factor
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Diabetic Retinopathy] explode all trees
#2 diabet*
#3r etinopath*
#4 #1 or #2 or #3
#5 MeSH descriptor: [Vitrectomy] explode all trees
#6 vitrectom*
#7 PPV*
#8 MeSH descriptor: [Sclerostomy] explode all trees
#9 sclerostom* or sclerectom*
#10 MeSH descriptor: [Vitreous Hemorrhage] this term only
#11 MeSH descriptor: [Vitreous Body] this term only
#12 hemorrhag* or haemorrhag*
#13 MeSH descriptor: [Postoperative Complications] explode all trees
#14 MeSH descriptor: [Recurrence] this term only
#15 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14
#16 MeSH descriptor: [Angiogenesis Inhibitors] explode all trees
#17 MeSH descriptor: [Angiogenesis Inducing Agents] explode all trees
#18 MeSH descriptor: [Endothelial Growth Factors] explode all trees
#19 MeSH descriptor: [Vascular Endothelial Growth Factors] explode all trees
#20 macugen* or pegaptanib* or lucentis* or rhufab* or ranibizumab* or bevacizumab* or avastin or aflibercept
#21 anti near/2 VEGF
#22 endothelial near/2 growth near/2 factor
#23 #16 or #17 or #18 or #19 or #20 or #21 or #22
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#24 #4 and #15 and #23
Appendix 2. MEDLINE (Ovid) search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp diabetic retinopathy/
14. diabet$.tw.
15. retinopath$.tw.
16. or/13-15
17. exp vitrectomy/
18. vitrectom$.tw.
19. PPV$.tw.
20. sclerostomy/
21. (sclerostom$ or sclerectom$).tw.
22. vitreous hemorrhage/
23. vitreous body/
24. (hemorrhag$ or haemorrhag$).tw.
25. exp postoperative complications/
26. or/17-25
27. exp angiogenesis inhibitors/
28. exp angiogenesis inducing agents/
29. exp endothelial growth factors/
30. exp vascular endothelial growth factors/
31. (macugen$ or pegaptanib$ or lucentis$ or rhufab$ or ranibizumab$ or bevacizumab$ or avastin or aflibercept).tw.
32. (anti adj2 VEGF$).tw.
33. (endothelial adj2 growth adj2 factor$).tw.
34. or/27-33
35. 16 and 26 and 34
36. 12 and 35
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville et al (Glanville 2006).
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Appendix 3. PubMed search strategy
((diabetic retinopathy[mesh]) OR (diabetes OR diabetic) OR (retinopathy)) AND ((vitrectomy[mesh]) OR (vitrectomy) OR (PPV)
OR (sclerostomy[mesh]) OR (sclerostomy OR sclerectomy)) OR (vitreous hemorrhage[mesh]) OR (vitreous body[mesh]) OR (hem-
orrhage OR haemorrhage) OR (postoperative complications[mesh]) OR (recurrence[mesh])) AND ((angiogenesis inhibitors[mesh])
OR (angiogenesis inducing agents[mesh]) OR (endothelial growth factors[mesh]) OR (vascular endothelial growth factors[mesh]) OR
(macugen OR pegaptanib OR lucentis OR rhufab OR ranibizumab OR bevacizumab OR avastin OR aflibercept) OR (endothelial
growth factor) OR (anti VEGF))
Appendix 4. EMBASE (Ovid) search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp diabetic retinopathy/
34. diabet$.tw.
35. retinopath$.tw.
36. or/33-35
37. exp vitrectomy/
38. vitrectom$.tw.
39. PPV$.tw.
40. sclerostomy/
41. (sclerostom$ or sclerectom$).tw.
42. vitreous hemorrhage/
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43. vitreous body/
44. (hemorrhag$ or haemorrhag$).tw.
45. exp postoperative complication/
46. recurrent disease/
47. or/37-46
48. exp angiogenesis/
49. exp angiogenesis inhibitors/
50. exp angiogenic factor/
51. exp endothelial cell growth factor/
52. exp vasculotropin/
53. (macugen$ or pegaptanib$ or lucentis$ or rhufab$ or ranibizumab$ or bevacizumab$ or avastin or aflibercept$).tw.
54. (anti adj2 VEGF$).tw.
55. (endothelial adj2 growth adj2 factor$).tw.
56. or/48-55
57. 36 and 47 and 56
58. 32 and 57
Appendix 5. LILACS search strategy
diabet$ or retinopath$ and vitrectom$ or PPV$ or sclerostom$ or sclerectom$ and vitreous or hemorrhag$ or haemorrhag$ or
postoperat$ or recur$
Appendix 6. ISRCTN search strategy
retinopathy AND vitrectomy AND haemorrhage
retinopathy AND vitrectomy AND hemorrhage
Appendix 7. ClinicalTrials.gov search strategy
Retinopathy AND Vitrectomy AND (Haemorrhage or Hemorrhage)
Appendix 8. ICTRP search strategy
Vitrectomy OR Haemorrhage OR Hemorrhage OR Vitroretinal OR Vitreous = Title AND Diabetic Retinopathy = Condtion AND
Macugen OR Pegaptanib OR Lucentis OR Rhufab OR Ranibizumab OR Bevacizumab OR Avastin OR Aflibercept = Intervention
WH A T ’ S N E W
Last assessed as up-to-date: 26 May 2015.
Date Event Description
22 October 2014 New citation required and conclusions have changed Issue 8, 2015: Eight new RCTs (Ahn 2011; El Batarny
2008; Elwan 2013; Farahvash 2011; Hernández-Da
Mota 2010; Manabe 2015; Sohn 2012; Zaman 2013)
were identified that met the inclusion criteria
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(Continued)
22 September 2014 New search has been performed Issue 8, 2015: Electronic searches were updated
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Due to the importance of postoperative retinal detachment, we included an additional analysis to enable patients and surgeons to make
a more informed choice when deciding to use IVB as an adjunct to vitrectomy.
Our protocol specified that we would exclude participants who received silicone oil endotamponade in the review analysis. Peer review
comments on our review questioned whether this would give rise to bias, and so we presented analyses of all participants and sensitivity
analyses excluding silicone oil cases. These additional analyses were not originally planned within the protocol.
Our protocol specified that we would present odds or risk ratios. We have chosen to present risk ratios as they are easier to interpret.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Angiogenesis Inhibitors [therapeutic use]; Antibodies, Monoclonal [therapeutic use]; Antibodies, Monoclonal, Humanized; Beva-
cizumab [therapeutic use]; Diabetic Retinopathy [∗surgery]; Intravitreal Injections; Postoperative Hemorrhage [∗prevention & control];
Preoperative Care; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A [antagonists & inhibitors]; Vascular
Endothelial Growth Factors [∗antagonists & inhibitors]; Vitrectomy [∗adverse effects]; Vitreous Hemorrhage [∗prevention & control]
MeSH check words
Humans
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